US20080166755A9 - Intracellular delivery of osteoinductive proteins and peptides - Google Patents
Intracellular delivery of osteoinductive proteins and peptides Download PDFInfo
- Publication number
- US20080166755A9 US20080166755A9 US10/806,915 US80691504A US2008166755A9 US 20080166755 A9 US20080166755 A9 US 20080166755A9 US 80691504 A US80691504 A US 80691504A US 2008166755 A9 US2008166755 A9 US 2008166755A9
- Authority
- US
- United States
- Prior art keywords
- seq
- lmp
- bmp
- polypeptide
- osteoinductive
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title claims abstract description 162
- 102000004196 processed proteins & peptides Human genes 0.000 title claims abstract description 131
- 108090000623 proteins and genes Proteins 0.000 title claims abstract description 124
- 102000004169 proteins and genes Human genes 0.000 title claims abstract description 119
- 230000002138 osteoinductive effect Effects 0.000 title claims abstract description 106
- 230000003834 intracellular effect Effects 0.000 title description 10
- 229920001184 polypeptide Polymers 0.000 claims abstract description 106
- 238000000034 method Methods 0.000 claims abstract description 76
- 238000010361 transduction Methods 0.000 claims abstract description 47
- 230000026683 transduction Effects 0.000 claims abstract description 47
- 230000004927 fusion Effects 0.000 claims abstract description 25
- 230000011164 ossification Effects 0.000 claims abstract description 16
- 230000015572 biosynthetic process Effects 0.000 claims abstract description 10
- 238000003786 synthesis reaction Methods 0.000 claims abstract description 9
- 210000004027 cell Anatomy 0.000 claims description 142
- 108010049931 Bone Morphogenetic Protein 2 Proteins 0.000 claims description 47
- 102100024506 Bone morphogenetic protein 2 Human genes 0.000 claims description 46
- 108010049870 Bone Morphogenetic Protein 7 Proteins 0.000 claims description 42
- 102100022544 Bone morphogenetic protein 7 Human genes 0.000 claims description 42
- 108020001507 fusion proteins Proteins 0.000 claims description 36
- 102000037865 fusion proteins Human genes 0.000 claims description 35
- 108010067219 Aggrecans Proteins 0.000 claims description 25
- 108010049974 Bone Morphogenetic Protein 6 Proteins 0.000 claims description 24
- 102100024505 Bone morphogenetic protein 4 Human genes 0.000 claims description 24
- 102100022525 Bone morphogenetic protein 6 Human genes 0.000 claims description 24
- 108010049955 Bone Morphogenetic Protein 4 Proteins 0.000 claims description 23
- 102000016611 Proteoglycans Human genes 0.000 claims description 22
- 108010067787 Proteoglycans Proteins 0.000 claims description 22
- 210000000130 stem cell Anatomy 0.000 claims description 19
- 150000007523 nucleic acids Chemical class 0.000 claims description 18
- 102000039446 nucleic acids Human genes 0.000 claims description 16
- 108020004707 nucleic acids Proteins 0.000 claims description 16
- 239000007943 implant Substances 0.000 claims description 15
- 102000004887 Transforming Growth Factor beta Human genes 0.000 claims description 14
- 108090001012 Transforming Growth Factor beta Proteins 0.000 claims description 14
- 230000014509 gene expression Effects 0.000 claims description 13
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 claims description 13
- 108010076504 Protein Sorting Signals Proteins 0.000 claims description 12
- 102000040430 polynucleotide Human genes 0.000 claims description 12
- 108091033319 polynucleotide Proteins 0.000 claims description 12
- 239000002157 polynucleotide Substances 0.000 claims description 12
- 239000003102 growth factor Substances 0.000 claims description 11
- 108700006830 Drosophila Antp Proteins 0.000 claims description 10
- 108010088535 Pep-1 peptide Proteins 0.000 claims description 9
- 241000124008 Mammalia Species 0.000 claims description 8
- 108010070875 Human Immunodeficiency Virus tat Gene Products Proteins 0.000 claims description 7
- 230000001939 inductive effect Effects 0.000 claims description 7
- 230000004072 osteoblast differentiation Effects 0.000 claims description 6
- 238000000746 purification Methods 0.000 claims description 6
- 239000000017 hydrogel Substances 0.000 claims description 5
- 230000000295 complement effect Effects 0.000 claims description 4
- 238000013518 transcription Methods 0.000 claims description 2
- 230000035897 transcription Effects 0.000 claims description 2
- 101710192602 Latent membrane protein 1 Proteins 0.000 claims 11
- 102000016284 Aggrecans Human genes 0.000 claims 1
- 238000001727 in vivo Methods 0.000 abstract description 16
- 235000018102 proteins Nutrition 0.000 description 105
- 108020004999 messenger RNA Proteins 0.000 description 59
- 102000007350 Bone Morphogenetic Proteins Human genes 0.000 description 39
- 108010007726 Bone Morphogenetic Proteins Proteins 0.000 description 39
- 229940112869 bone morphogenetic protein Drugs 0.000 description 37
- 102100036601 Aggrecan core protein Human genes 0.000 description 25
- 101710121660 PDZ and LIM domain protein 7 Proteins 0.000 description 25
- 102100033337 PDZ and LIM domain protein 7 Human genes 0.000 description 25
- 230000000694 effects Effects 0.000 description 25
- 238000004519 manufacturing process Methods 0.000 description 25
- 101001134647 Homo sapiens PDZ and LIM domain protein 7 Proteins 0.000 description 18
- 230000001965 increasing effect Effects 0.000 description 18
- 108020004414 DNA Proteins 0.000 description 17
- 235000001014 amino acid Nutrition 0.000 description 17
- 238000002474 experimental method Methods 0.000 description 17
- 102000045246 noggin Human genes 0.000 description 17
- 108700007229 noggin Proteins 0.000 description 17
- 229940024606 amino acid Drugs 0.000 description 16
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 15
- 125000003275 alpha amino acid group Chemical group 0.000 description 15
- 150000001413 amino acids Chemical class 0.000 description 15
- 102000049444 human PDLIM7 Human genes 0.000 description 15
- 210000001519 tissue Anatomy 0.000 description 15
- 239000013598 vector Substances 0.000 description 15
- 241000700605 Viruses Species 0.000 description 13
- 239000002299 complementary DNA Substances 0.000 description 12
- 239000002773 nucleotide Substances 0.000 description 12
- 125000003729 nucleotide group Chemical group 0.000 description 12
- 238000003753 real-time PCR Methods 0.000 description 12
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 11
- 229940072056 alginate Drugs 0.000 description 11
- 235000010443 alginic acid Nutrition 0.000 description 11
- 229920000615 alginic acid Polymers 0.000 description 11
- 210000000988 bone and bone Anatomy 0.000 description 11
- 239000000047 product Substances 0.000 description 11
- 238000006467 substitution reaction Methods 0.000 description 11
- 241000283973 Oryctolagus cuniculus Species 0.000 description 10
- 108010007945 Smad Proteins Proteins 0.000 description 10
- 102000007374 Smad Proteins Human genes 0.000 description 10
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 10
- 230000002018 overexpression Effects 0.000 description 10
- 230000003827 upregulation Effects 0.000 description 10
- 239000000243 solution Substances 0.000 description 9
- 102000008186 Collagen Human genes 0.000 description 8
- 108010035532 Collagen Proteins 0.000 description 8
- 108700042652 LMP-2 Proteins 0.000 description 8
- 241000700159 Rattus Species 0.000 description 8
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 8
- 229920001436 collagen Polymers 0.000 description 8
- 239000001963 growth medium Substances 0.000 description 8
- 238000012453 sprague-dawley rat model Methods 0.000 description 8
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 8
- 241000701161 unidentified adenovirus Species 0.000 description 8
- -1 BMP-12 Proteins 0.000 description 7
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 7
- 241000282414 Homo sapiens Species 0.000 description 7
- 238000000338 in vitro Methods 0.000 description 7
- 102000005962 receptors Human genes 0.000 description 7
- 108020003175 receptors Proteins 0.000 description 7
- 239000000523 sample Substances 0.000 description 7
- 239000011780 sodium chloride Substances 0.000 description 7
- 230000001225 therapeutic effect Effects 0.000 description 7
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 6
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 6
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 6
- 108091028043 Nucleic acid sequence Proteins 0.000 description 6
- 239000011324 bead Substances 0.000 description 6
- 239000000872 buffer Substances 0.000 description 6
- 230000000875 corresponding effect Effects 0.000 description 6
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 6
- 239000002609 medium Substances 0.000 description 6
- 238000011069 regeneration method Methods 0.000 description 6
- 239000000126 substance Substances 0.000 description 6
- 239000004202 carbamide Substances 0.000 description 5
- 238000006243 chemical reaction Methods 0.000 description 5
- 239000012091 fetal bovine serum Substances 0.000 description 5
- 238000002513 implantation Methods 0.000 description 5
- 238000004264 monolayer culture Methods 0.000 description 5
- 238000011587 new zealand white rabbit Methods 0.000 description 5
- 230000004819 osteoinduction Effects 0.000 description 5
- 230000008929 regeneration Effects 0.000 description 5
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 4
- 108010035601 Coxsackie and Adenovirus Receptor Like Membrane Protein Proteins 0.000 description 4
- 102000008198 Coxsackie and Adenovirus Receptor Like Membrane Protein Human genes 0.000 description 4
- 229910019142 PO4 Inorganic materials 0.000 description 4
- 229930182555 Penicillin Natural products 0.000 description 4
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 4
- 230000008468 bone growth Effects 0.000 description 4
- 210000000170 cell membrane Anatomy 0.000 description 4
- 208000015181 infectious disease Diseases 0.000 description 4
- 210000000963 osteoblast Anatomy 0.000 description 4
- 229940049954 penicillin Drugs 0.000 description 4
- 239000013612 plasmid Substances 0.000 description 4
- 239000002356 single layer Substances 0.000 description 4
- 229910000029 sodium carbonate Inorganic materials 0.000 description 4
- 229960005322 streptomycin Drugs 0.000 description 4
- 238000001890 transfection Methods 0.000 description 4
- 101150061927 BMP2 gene Proteins 0.000 description 3
- 102100022545 Bone morphogenetic protein 8B Human genes 0.000 description 3
- 102000004127 Cytokines Human genes 0.000 description 3
- 108090000695 Cytokines Proteins 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 3
- 229920002683 Glycosaminoglycan Polymers 0.000 description 3
- 108010090290 Growth Differentiation Factor 2 Proteins 0.000 description 3
- 102100040892 Growth/differentiation factor 2 Human genes 0.000 description 3
- 101000899368 Homo sapiens Bone morphogenetic protein 8B Proteins 0.000 description 3
- 206010061246 Intervertebral disc degeneration Diseases 0.000 description 3
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 3
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 3
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 3
- 229930182816 L-glutamine Natural products 0.000 description 3
- 101150086605 Runx2 gene Proteins 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 208000037065 Subacute sclerosing leukoencephalitis Diseases 0.000 description 3
- 206010042297 Subacute sclerosing panencephalitis Diseases 0.000 description 3
- 102000046299 Transforming Growth Factor beta1 Human genes 0.000 description 3
- 101800002279 Transforming growth factor beta-1 Proteins 0.000 description 3
- 238000000246 agarose gel electrophoresis Methods 0.000 description 3
- 230000000735 allogeneic effect Effects 0.000 description 3
- 230000004071 biological effect Effects 0.000 description 3
- 230000000903 blocking effect Effects 0.000 description 3
- 238000011109 contamination Methods 0.000 description 3
- 230000002950 deficient Effects 0.000 description 3
- 239000012634 fragment Substances 0.000 description 3
- 238000009396 hybridization Methods 0.000 description 3
- 230000033001 locomotion Effects 0.000 description 3
- 230000007774 longterm Effects 0.000 description 3
- 210000004705 lumbosacral region Anatomy 0.000 description 3
- 239000011159 matrix material Substances 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 230000010076 replication Effects 0.000 description 3
- 230000011664 signaling Effects 0.000 description 3
- 238000001356 surgical procedure Methods 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- 230000017423 tissue regeneration Effects 0.000 description 3
- 230000003612 virological effect Effects 0.000 description 3
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 2
- 108010049976 Bone Morphogenetic Protein 5 Proteins 0.000 description 2
- 102100022526 Bone morphogenetic protein 5 Human genes 0.000 description 2
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- 238000002965 ELISA Methods 0.000 description 2
- 238000012286 ELISA Assay Methods 0.000 description 2
- 102100031780 Endonuclease Human genes 0.000 description 2
- ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 2
- 102000003886 Glycoproteins Human genes 0.000 description 2
- 108090000288 Glycoproteins Proteins 0.000 description 2
- 102100035368 Growth/differentiation factor 6 Human genes 0.000 description 2
- 101710204281 Growth/differentiation factor 6 Proteins 0.000 description 2
- 241000725303 Human immunodeficiency virus Species 0.000 description 2
- 238000012404 In vitro experiment Methods 0.000 description 2
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 2
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 2
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 2
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 108090000526 Papain Proteins 0.000 description 2
- 108091093037 Peptide nucleic acid Proteins 0.000 description 2
- 239000004365 Protease Substances 0.000 description 2
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 2
- 229920002684 Sepharose Polymers 0.000 description 2
- 241000700584 Simplexvirus Species 0.000 description 2
- 229930003268 Vitamin C Natural products 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 238000009825 accumulation Methods 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 239000011543 agarose gel Substances 0.000 description 2
- 235000004279 alanine Nutrition 0.000 description 2
- 230000014461 bone development Effects 0.000 description 2
- 210000001185 bone marrow Anatomy 0.000 description 2
- 210000004899 c-terminal region Anatomy 0.000 description 2
- 239000006285 cell suspension Substances 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- SMNPLAKEGAEPJD-UHFFFAOYSA-N chembl34922 Chemical compound Cl.Cl.Cl.C1CN(C)CCN1C1=CC=C(NC(=N2)C=3C=C4N=C(NC4=CC=3)C=3C=CC(O)=CC=3)C2=C1 SMNPLAKEGAEPJD-UHFFFAOYSA-N 0.000 description 2
- 239000003636 conditioned culture medium Substances 0.000 description 2
- 210000004748 cultured cell Anatomy 0.000 description 2
- SUYVUBYJARFZHO-RRKCRQDMSA-N dATP Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@H]1C[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 SUYVUBYJARFZHO-RRKCRQDMSA-N 0.000 description 2
- RGWHQCVHVJXOKC-SHYZEUOFSA-N dCTP Chemical compound O=C1N=C(N)C=CN1[C@@H]1O[C@H](CO[P@](O)(=O)O[P@](O)(=O)OP(O)(O)=O)[C@@H](O)C1 RGWHQCVHVJXOKC-SHYZEUOFSA-N 0.000 description 2
- NHVNXKFIZYSCEB-XLPZGREQSA-N dTTP Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)C1 NHVNXKFIZYSCEB-XLPZGREQSA-N 0.000 description 2
- 230000007547 defect Effects 0.000 description 2
- 208000018180 degenerative disc disease Diseases 0.000 description 2
- 238000012217 deletion Methods 0.000 description 2
- 230000037430 deletion Effects 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 230000029087 digestion Effects 0.000 description 2
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 231100000673 dose–response relationship Toxicity 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 210000002889 endothelial cell Anatomy 0.000 description 2
- 239000013604 expression vector Substances 0.000 description 2
- 238000001415 gene therapy Methods 0.000 description 2
- 230000035876 healing Effects 0.000 description 2
- 210000003958 hematopoietic stem cell Anatomy 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 208000014674 injury Diseases 0.000 description 2
- 238000003780 insertion Methods 0.000 description 2
- 230000037431 insertion Effects 0.000 description 2
- 208000021600 intervertebral disc degenerative disease Diseases 0.000 description 2
- 210000000265 leukocyte Anatomy 0.000 description 2
- 238000012417 linear regression Methods 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- 210000002901 mesenchymal stem cell Anatomy 0.000 description 2
- 210000002894 multi-fate stem cell Anatomy 0.000 description 2
- 210000000663 muscle cell Anatomy 0.000 description 2
- 229940055729 papain Drugs 0.000 description 2
- 235000019834 papain Nutrition 0.000 description 2
- 239000002953 phosphate buffered saline Substances 0.000 description 2
- 238000002601 radiography Methods 0.000 description 2
- 238000010807 real-time PCR kit Methods 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 108091008146 restriction endonucleases Proteins 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 2
- 238000010561 standard procedure Methods 0.000 description 2
- 230000008733 trauma Effects 0.000 description 2
- 235000019154 vitamin C Nutrition 0.000 description 2
- 239000011718 vitamin C Substances 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 238000001262 western blot Methods 0.000 description 2
- XZKIHKMTEMTJQX-UHFFFAOYSA-N 4-Nitrophenyl Phosphate Chemical compound OP(O)(=O)OC1=CC=C([N+]([O-])=O)C=C1 XZKIHKMTEMTJQX-UHFFFAOYSA-N 0.000 description 1
- SQDAZGGFXASXDW-UHFFFAOYSA-N 5-bromo-2-(trifluoromethoxy)pyridine Chemical compound FC(F)(F)OC1=CC=C(Br)C=N1 SQDAZGGFXASXDW-UHFFFAOYSA-N 0.000 description 1
- 101710192389 Aggrecan core protein Proteins 0.000 description 1
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 1
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 1
- 108091093088 Amplicon Proteins 0.000 description 1
- 108700031308 Antennapedia Homeodomain Proteins 0.000 description 1
- 101150019028 Antp gene Proteins 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 1
- 241000972773 Aulopiformes Species 0.000 description 1
- 241000713838 Avian myeloblastosis virus Species 0.000 description 1
- 102000004954 Biglycan Human genes 0.000 description 1
- 108090001138 Biglycan Proteins 0.000 description 1
- 108010049951 Bone Morphogenetic Protein 3 Proteins 0.000 description 1
- 208000020084 Bone disease Diseases 0.000 description 1
- 101710118482 Bone morphogenetic protein 10 Proteins 0.000 description 1
- 102100028726 Bone morphogenetic protein 10 Human genes 0.000 description 1
- 102000003928 Bone morphogenetic protein 15 Human genes 0.000 description 1
- 108090000349 Bone morphogenetic protein 15 Proteins 0.000 description 1
- 102100024504 Bone morphogenetic protein 3 Human genes 0.000 description 1
- 125000001433 C-terminal amino-acid group Chemical group 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 108010001857 Cell Surface Receptors Proteins 0.000 description 1
- 102000000844 Cell Surface Receptors Human genes 0.000 description 1
- 229920001287 Chondroitin sulfate Polymers 0.000 description 1
- 108020004705 Codon Proteins 0.000 description 1
- 102000012422 Collagen Type I Human genes 0.000 description 1
- 108010022452 Collagen Type I Proteins 0.000 description 1
- 102000000503 Collagen Type II Human genes 0.000 description 1
- 108010041390 Collagen Type II Proteins 0.000 description 1
- 102000029816 Collagenase Human genes 0.000 description 1
- 108060005980 Collagenase Proteins 0.000 description 1
- LEVWYRKDKASIDU-QWWZWVQMSA-N D-cystine Chemical compound OC(=O)[C@H](N)CSSC[C@@H](N)C(O)=O LEVWYRKDKASIDU-QWWZWVQMSA-N 0.000 description 1
- 238000001712 DNA sequencing Methods 0.000 description 1
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 1
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 1
- 102000004237 Decorin Human genes 0.000 description 1
- 108090000738 Decorin Proteins 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 241000255581 Drosophila <fruit fly, genus> Species 0.000 description 1
- 102000016942 Elastin Human genes 0.000 description 1
- 108010014258 Elastin Proteins 0.000 description 1
- 102100040897 Embryonic growth/differentiation factor 1 Human genes 0.000 description 1
- 102000009024 Epidermal Growth Factor Human genes 0.000 description 1
- 102000009123 Fibrin Human genes 0.000 description 1
- 108010073385 Fibrin Proteins 0.000 description 1
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 1
- 102000018233 Fibroblast Growth Factor Human genes 0.000 description 1
- 108050007372 Fibroblast Growth Factor Proteins 0.000 description 1
- 102000017177 Fibromodulin Human genes 0.000 description 1
- 108010013996 Fibromodulin Proteins 0.000 description 1
- 229920001917 Ficoll Polymers 0.000 description 1
- 206010017076 Fracture Diseases 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 108010090296 Growth Differentiation Factor 1 Proteins 0.000 description 1
- 108010041881 Growth Differentiation Factor 10 Proteins 0.000 description 1
- 108010090293 Growth Differentiation Factor 3 Proteins 0.000 description 1
- 102000004858 Growth differentiation factor-9 Human genes 0.000 description 1
- 108090001086 Growth differentiation factor-9 Proteins 0.000 description 1
- 102100040895 Growth/differentiation factor 10 Human genes 0.000 description 1
- 101710194452 Growth/differentiation factor 11 Proteins 0.000 description 1
- 102100040898 Growth/differentiation factor 11 Human genes 0.000 description 1
- 102100035364 Growth/differentiation factor 3 Human genes 0.000 description 1
- 102100035379 Growth/differentiation factor 5 Human genes 0.000 description 1
- 101710204282 Growth/differentiation factor 5 Proteins 0.000 description 1
- 102100039939 Growth/differentiation factor 8 Human genes 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101000762379 Homo sapiens Bone morphogenetic protein 4 Proteins 0.000 description 1
- 101000988394 Homo sapiens PDZ and LIM domain protein 5 Proteins 0.000 description 1
- 241000713772 Human immunodeficiency virus 1 Species 0.000 description 1
- 101000668058 Infectious salmon anemia virus (isolate Atlantic salmon/Norway/810/9/99) RNA-directed RNA polymerase catalytic subunit Proteins 0.000 description 1
- 108090000723 Insulin-Like Growth Factor I Proteins 0.000 description 1
- 102000004218 Insulin-Like Growth Factor I Human genes 0.000 description 1
- 208000012659 Joint disease Diseases 0.000 description 1
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 1
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 1
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
- 102000011681 Lumican Human genes 0.000 description 1
- 108010076371 Lumican Proteins 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 102000003939 Membrane transport proteins Human genes 0.000 description 1
- 108090000301 Membrane transport proteins Proteins 0.000 description 1
- 101100165560 Mus musculus Bmp7 gene Proteins 0.000 description 1
- 108010056852 Myostatin Proteins 0.000 description 1
- 238000000636 Northern blotting Methods 0.000 description 1
- 108091005461 Nucleic proteins Proteins 0.000 description 1
- 206010031243 Osteogenesis imperfecta Diseases 0.000 description 1
- 208000001132 Osteoporosis Diseases 0.000 description 1
- 102100029181 PDZ and LIM domain protein 5 Human genes 0.000 description 1
- 229920000954 Polyglycolide Polymers 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- 239000004372 Polyvinyl alcohol Substances 0.000 description 1
- 101710098940 Pro-epidermal growth factor Proteins 0.000 description 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
- 108010059712 Pronase Proteins 0.000 description 1
- 101710149951 Protein Tat Proteins 0.000 description 1
- 239000013614 RNA sample Substances 0.000 description 1
- 238000011529 RT qPCR Methods 0.000 description 1
- 101001134645 Rattus norvegicus PDZ and LIM domain protein 7 Proteins 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- 238000002105 Southern blotting Methods 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 101710192266 Tegument protein VP22 Proteins 0.000 description 1
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
- 239000004473 Threonine Substances 0.000 description 1
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- JRMSLDWZFJZLAS-UHFFFAOYSA-M [7-(dimethylamino)-1,9-dimethylphenothiazin-3-ylidene]-dimethylazanium;chloride Chemical compound [Cl-].CC1=CC(N(C)C)=CC2=[S+]C3=CC(N(C)C)=CC(C)=C3N=C21 JRMSLDWZFJZLAS-UHFFFAOYSA-M 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 210000001789 adipocyte Anatomy 0.000 description 1
- 125000000539 amino acid group Chemical group 0.000 description 1
- BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 1
- 229910052921 ammonium sulfate Inorganic materials 0.000 description 1
- 235000011130 ammonium sulphate Nutrition 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 238000005571 anion exchange chromatography Methods 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 208000037873 arthrodesis Diseases 0.000 description 1
- 229940072107 ascorbate Drugs 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 229960001230 asparagine Drugs 0.000 description 1
- 235000009582 asparagine Nutrition 0.000 description 1
- 229940009098 aspartate Drugs 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 229920002988 biodegradable polymer Polymers 0.000 description 1
- 239000004621 biodegradable polymer Substances 0.000 description 1
- 230000033558 biomineral tissue development Effects 0.000 description 1
- 210000002798 bone marrow cell Anatomy 0.000 description 1
- 210000002805 bone matrix Anatomy 0.000 description 1
- 230000018678 bone mineralization Effects 0.000 description 1
- 230000010478 bone regeneration Effects 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 244000309466 calf Species 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 210000000845 cartilage Anatomy 0.000 description 1
- 230000022159 cartilage development Effects 0.000 description 1
- 239000000919 ceramic Substances 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- YDQXYRCYDMRJGD-UHFFFAOYSA-N chloroform;phenol;thiocyanic acid Chemical compound SC#N.ClC(Cl)Cl.OC1=CC=CC=C1 YDQXYRCYDMRJGD-UHFFFAOYSA-N 0.000 description 1
- 229940059329 chondroitin sulfate Drugs 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 239000000515 collagen sponge Substances 0.000 description 1
- 229940096422 collagen type i Drugs 0.000 description 1
- 229960002424 collagenase Drugs 0.000 description 1
- 238000002591 computed tomography Methods 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 108010010201 core binding factor alpha Proteins 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 238000013211 curve analysis Methods 0.000 description 1
- 229960003067 cystine Drugs 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000003412 degenerative effect Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 229920002549 elastin Polymers 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 238000000295 emission spectrum Methods 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 239000003797 essential amino acid Substances 0.000 description 1
- 235000020776 essential amino acid Nutrition 0.000 description 1
- 238000000695 excitation spectrum Methods 0.000 description 1
- 238000013401 experimental design Methods 0.000 description 1
- 229950003499 fibrin Drugs 0.000 description 1
- 229940126864 fibroblast growth factor Drugs 0.000 description 1
- 102000034356 gene-regulatory proteins Human genes 0.000 description 1
- 108091006104 gene-regulatory proteins Proteins 0.000 description 1
- 239000003862 glucocorticoid Substances 0.000 description 1
- 229930195712 glutamate Natural products 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 229960002743 glutamine Drugs 0.000 description 1
- 229960002449 glycine Drugs 0.000 description 1
- 230000005484 gravity Effects 0.000 description 1
- 238000003306 harvesting Methods 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 230000002962 histologic effect Effects 0.000 description 1
- 238000004191 hydrophobic interaction chromatography Methods 0.000 description 1
- 229910052588 hydroxylapatite Inorganic materials 0.000 description 1
- 230000008676 import Effects 0.000 description 1
- 230000001976 improved effect Effects 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 230000008316 intracellular mechanism Effects 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 229960000310 isoleucine Drugs 0.000 description 1
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 1
- BPHPUYQFMNQIOC-NXRLNHOXSA-N isopropyl beta-D-thiogalactopyranoside Chemical compound CC(C)S[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O BPHPUYQFMNQIOC-NXRLNHOXSA-N 0.000 description 1
- 101150066555 lacZ gene Proteins 0.000 description 1
- 210000003041 ligament Anatomy 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 238000004020 luminiscence type Methods 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000009061 membrane transport Effects 0.000 description 1
- MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 229960004452 methionine Drugs 0.000 description 1
- 239000004005 microsphere Substances 0.000 description 1
- 230000011278 mitosis Effects 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 239000002077 nanosphere Substances 0.000 description 1
- 229920005615 natural polymer Polymers 0.000 description 1
- 230000024121 nodulation Effects 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- QYSGYZVSCZSLHT-UHFFFAOYSA-N octafluoropropane Chemical compound FC(F)(F)C(F)(F)C(F)(F)F QYSGYZVSCZSLHT-UHFFFAOYSA-N 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 230000000399 orthopedic effect Effects 0.000 description 1
- 238000002559 palpation Methods 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- XYJRXVWERLGGKC-UHFFFAOYSA-D pentacalcium;hydroxide;triphosphate Chemical compound [OH-].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O XYJRXVWERLGGKC-UHFFFAOYSA-D 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 210000004976 peripheral blood cell Anatomy 0.000 description 1
- 210000000578 peripheral nerve Anatomy 0.000 description 1
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 210000001778 pluripotent stem cell Anatomy 0.000 description 1
- 229920000747 poly(lactic acid) Polymers 0.000 description 1
- 230000008488 polyadenylation Effects 0.000 description 1
- 229920001610 polycaprolactone Polymers 0.000 description 1
- 239000004632 polycaprolactone Substances 0.000 description 1
- 229920000728 polyester Polymers 0.000 description 1
- 229920000570 polyether Polymers 0.000 description 1
- 239000004633 polyglycolic acid Substances 0.000 description 1
- 239000004626 polylactic acid Substances 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 210000004896 polypeptide structure Anatomy 0.000 description 1
- 229920001299 polypropylene fumarate Polymers 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 230000000135 prohibitive effect Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 238000009163 protein therapy Methods 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 102000037983 regulatory factors Human genes 0.000 description 1
- 108091008025 regulatory factors Proteins 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 238000010839 reverse transcription Methods 0.000 description 1
- 238000003757 reverse transcription PCR Methods 0.000 description 1
- 235000019515 salmon Nutrition 0.000 description 1
- 239000012488 sample solution Substances 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 238000013207 serial dilution Methods 0.000 description 1
- 229960001153 serine Drugs 0.000 description 1
- UQDJGEHQDNVPGU-UHFFFAOYSA-N serine phosphoethanolamine Chemical compound [NH3+]CCOP([O-])(=O)OCC([NH3+])C([O-])=O UQDJGEHQDNVPGU-UHFFFAOYSA-N 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 210000001082 somatic cell Anatomy 0.000 description 1
- 238000000527 sonication Methods 0.000 description 1
- 210000000278 spinal cord Anatomy 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 239000011550 stock solution Substances 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 229910021653 sulphate ion Inorganic materials 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 229920001059 synthetic polymer Polymers 0.000 description 1
- 229940037128 systemic glucocorticoids Drugs 0.000 description 1
- 210000002435 tendon Anatomy 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 238000011285 therapeutic regimen Methods 0.000 description 1
- 229960002898 threonine Drugs 0.000 description 1
- 210000001541 thymus gland Anatomy 0.000 description 1
- 230000036962 time dependent Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 108091006106 transcriptional activators Proteins 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000014616 translation Effects 0.000 description 1
- 230000005945 translocation Effects 0.000 description 1
- 230000032258 transport Effects 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 229940078499 tricalcium phosphate Drugs 0.000 description 1
- 229910000391 tricalcium phosphate Inorganic materials 0.000 description 1
- 235000019731 tricalcium phosphate Nutrition 0.000 description 1
- 239000001226 triphosphate Substances 0.000 description 1
- 235000011178 triphosphate Nutrition 0.000 description 1
- UNXRWKVEANCORM-UHFFFAOYSA-N triphosphoric acid Chemical compound OP(O)(=O)OP(O)(=O)OP(O)(O)=O UNXRWKVEANCORM-UHFFFAOYSA-N 0.000 description 1
- 229960004441 tyrosine Drugs 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- 239000004474 valine Substances 0.000 description 1
- 230000007502 viral entry Effects 0.000 description 1
- 239000013603 viral vector Substances 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/43504—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates
- C07K14/43563—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from insects
- C07K14/43577—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from insects from flies
- C07K14/43581—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from insects from flies from Drosophila
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4702—Regulators; Modulating activity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
- C07K14/495—Transforming growth factor [TGF]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
- C07K14/51—Bone morphogenetic factor; Osteogenins; Osteogenic factor; Bone-inducing factor
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16311—Human Immunodeficiency Virus, HIV concerning HIV regulatory proteins
- C12N2740/16322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
Definitions
- the present invention relates generally to osteoinductive proteins and methods for the delivery of those proteins into cells. More specifically, the invention relates to osteoinductive proteins such as LIM mineralization proteins (LMPs), bone morphogenetic proteins (BMPs) and Smad proteins, conjugates of such osteoinductive proteins with protein transduction domains (PTDs), conjugates of PTDs and nucleic acids comprising nucleotide sequences encoding osteoinductive proteins, and to the transduction of these conjugates into cells. Furthermore, the invention relates to the use of PTD/osteoinductive protein conjugates to promote bone growth and disc regeneration.
- LMPs LIM mineralization proteins
- BMPs bone morphogenetic proteins
- Smad proteins conjugates of such osteoinductive proteins with protein transduction domains (PTDs), conjugates of PTDs and nucleic acids comprising nucleotide sequences encoding osteoinductive proteins
- PTDs protein transduction domains
- nucleic acids comprising nucleotide sequences encoding osteoinductive proteins
- Tissue regeneration is an important component of the healing process subsequent to disease, trauma, or surgery.
- disease or trauma produces bone defect, for example, or where a surgical procedure such as insertion of an autograft or allograft, bone bridge, or bone fusion is used to correct a bone defect
- bone regeneration is a central goal of recovery. It is not, however, a goal that is always or easily achieved and much research has been devoted to newer and more effective ways to promote tissue repair and regeneration.
- Elimination of joint motion by creation of a bone bridge is a common orthopedic strategy for the treatment of degenerative spine and joint disorders. Failure of spine fusion can occur in as many as forty-five percent of the patients who undergo the procedure, leaving them with continued pain, repeated surgeries, medical costs, and overall therapeutic failure.
- Intracellular and extracellular osteoinductive proteins promote bone growth and repair and constitute potential targets for therapeutic use.
- Such proteins include the bone morphogenetic proteins and the LIM mineralization proteins.
- BMPs have been shown to stimulate bone growth in vivo and LMPs, particularly LMP-1 and LMP-3, have a more upstream effect on osteoinduction, as evidenced by the fact that inhibition of LMP-1 expression blocks nodule formation that would normally be stimulated by glucocorticoids or BMP-6. Since they are considered “extracellular” proteins, acting via interaction with cell surface receptors, very high doses of bone morphogenetic proteins are required to achieve consistent effects in humans. Since the manufacturing costs of BMPs is generally high, this can mean that the cost of therapy is prohibitive. Therefore, although BMPs have demonstrated efficacy and are a viable therapeutic aid to osteoinduction, it would be beneficial to develop an alternate therapy that might be more cost-effective and possibly even more therapeutically effective.
- LMPs Delivery of LMPs to the intracellular environment provides an attractive therapeutic regimen. This can be accomplished by transfection of cells with plasmids comprising a nucleotide sequence encoding a LIM mineralization protein, or can be done by infection of target cells with a viral vector carrying the nucleotide sequence of LMP. Each of these techniques has limitations, however. Plasmid transfection generally requires that cells be isolated for transfection and then implanted after transfection. Viral delivery generally requires that the appropriate receptor be located on the surface of the target cell in order to facilitate viral entry into the cell.
- osteoinductive proteins and peptides there is tremendous potential for the use of osteoinductive proteins and peptides, particularly for the use of those proteins and peptides that act via an intracellular mechanism. What is needed is a method of delivery of effective intracellular osteoinductive proteins and peptides into cells.
- the present invention provides a method of producing a cell-permeable osteoinductive polypeptide comprising introducing into a suitable host cell an expression construct encoding a cell-permeable polypeptide and an osteoinductive polypeptide positioned so that the osteoinductive polypeptide is expressed as part of a fusion protein with the cell-permeable polypeptide.
- the expression construct generally contains a promoter positioned to direct transcription of the polynucleotide sequence encoding the fusion product.
- the expression construct may further comprise a purification tag.
- the cell-permeable polypeptide may be chosen from the group consisting of HIV-TAT, VP-22, a growth factor signal peptide sequence, Pep-1, and a Drosophila Antp peptide.
- the osteoinductive polypeptide may be chosen from the group consisting of LMP-1, LMP-3, SEQ ID NO 1, SEQ ID NO 2, SEQ ID NO 3, SEQ ID NO 4, SEQ ID NO 5, SEQ ID NO 6, SEQ ID NO 7, SEQ ID NO 8, BMP-2, BMP-4, BMP-6, BMP-7, TGF-beta 1 and Smad.
- the invention provides osteoinductive polypeptides chosen from among the group consisting of SEQ ID NO 1, SEQ ID NO 2, SEQ ID NO 3, SEQ ID NO 4, SEQ ID NO 5, SEQ ID NO 6, SEQ ID NO 7, and SEQ ID NO 8, or combinations thereof.
- the invention also provides a method of inducing bone formation in a mammal comprising administering an effective amount of a fusion polypeptide comprising a protein transduction domain and at least one osteoinductive polypeptide.
- the fusion polypeptide may be administered as an implant and may be administered to at least one multipotent progenitor cell, which can be implanted into a mammal to promote osteoinduction.
- the invention also provides a polynucleotide encoding a fusion protein comprising a protein transduction domain and at least one osteoinductive polypeptide, the protein transduction domain being chosen from among a variety of protein transduction, membrane-translocation, and other similar polypeptides represented, for example, by HIV-TAT, VP-22, a growth factor signal peptide sequence, Pep-1, and a Drosophila Antp peptide.
- the osteoinductive polypeptide may be chosen from the group consisting of LMP-1, LMP-3, SEQ ID NO 1, SEQ ID NO 2, SEQ ID NO 3, SEQ ID NO 4, SEQ ID NO 5, SEQ ID NO 6, SEQ ID NO 7, SEQ ID NO 8, BMP-2, BMP-4, BMP-6, BMP-7, TGF-beta 1 and Smad.
- a method of inducing proteoglycan synthesis in a mammal comprises administering an effective amount of a fusion polypeptide comprising a protein transduction domain and at least one osteoinductive polypeptide.
- the fusion polypeptide may be administered as an implant, and may be administered to at least one multipotent progenitor cell.
- An isolated fusion polypeptide comprising a membrane-translocating peptide operably linked to an osteoinductive polypeptide is provided by the invention.
- the membrane-translocating peptide may be chosen from the group consisting of HIV-TAT, VP-22, a growth factor signal peptide sequence, Pep-1, and a Drosophila Antp peptide and the osteoinductive polypeptide may be chosen from the group consisting of LMP-1, LMP-3, SEQ ID NO 1, SEQ ID NO 2, SEQ ID NO 3, SEQ ID NO 4, SEQ ID NO 5, SEQ ID NO 6, SEQ ID NO 7, SEQ ID NO 8, BMP-2, BMP-4, BMP-6, BMP-7, TGF-beta 1 and Smad.
- the invention provides a method of inducing osteoblast differentiation in a progenitor cell, the method comprising administering to the progenitor cell an effective amount of a fusion polypeptide comprising a protein transduction domain and at least one osteoinductive polypeptide.
- the protein transduction domain can be chosen from the group represented by HIV-TAT, VP-22, a growth factor signal peptide sequence, Pep-1, and Drosophila Antp polypeptides and the osteoinductive polypeptide may be chosen from the group represented by LMP-1, LMP-3, SEQ ID NO 1, SEQ ID NO 2, SEQ ID NO 3, SEQ ID NO 4, SEQ ID NO 5, SEQ ID NO 6, SEQ ID NO 7, SEQ ID NO 8, BMP-2, BMP-4, BMP-6, BMP-7, TGF-beta 1 and Smad.
- FIG. 1 is a graph of BMP protein levels in media 6 days after treatment of annulus cells with LMP-1 (AdLMP-1 at MOI 25).
- the protein levels of BMP-2 and BMP-7 were increased significantly but BMP-4 and BMP-6 protein levels were not significantly different from media of untreated control cells. Each result is expressed as a ratio in proportion to the value from untreated cells. The mean and SEM for seven samples are reported. (* p ⁇ 0.05 ** p ⁇ 0.01 versus NT).
- FIG. 2 illustrates time-course BMP mRNA levels after treatment of annulus cells with LMP-1 (AdLMP-1 at MOI 25).
- BMP-2 mRNA level was upregulated significantly as early as 12 hours after AdLMP-1 treatement and reached a plateau 3 days after AdLMP-1 treatment.
- BMP-7 mRNA level was significantly increased 3 days after AdLMP-1 treatment.
- Each result is expressed as a ratio to values from untreated cells at the same time point. The mean and SEM for six samples are reported. (** p ⁇ 0.01 versus NT for corresponding time point).
- FIG. 3 graphs aggrecan mRNA level in annulus cells after treatment with LMP-1 (AdLMP-1) measured by realtime PCR.
- the mRNA level of aggrecan was significantly increased 6 days after treatment with AdLMP-1 at MOI 25 as compared to untreated cells.
- the mRNA level of aggrecan was not changed in cells treated with AdLacZ as compared to untreated cells. Each result is expressed as a ratio to values from untreated cells. The mean and SEM for nine samples are reported.
- AdLMP-1 MOI 25
- AdLacZ MOI 25. (** p ⁇ 0.01 versus NT).
- FIG. 4 is a table summarizing parameters and results of LMP-1 administration via a PTD/LMP-1 fusion protein in Harlan athymic rats.
- FIG. 5 is a table summarizing parameters and results of LMP-1 administration via a PTD/LMP-1 fusion protein in New Zealand White rabbits.
- FIG. 6 is a table summarizing results of administration of the indicated osteoinductive peptides via a PTD/peptide fusion protein in Harlan athymic rats, and, where indicated, New Zealand White rabbits. Bone growth was detected by x-ray, and, where indicated, was also palpable.
- the inventors have discovered that a fusion protein comprising a protein transduction polypeptide and an osteoinductive polypeptide can be effectively used to promote bone development and intervertebral disc regeneration in vivo.
- the invention therefore provides osteoinductive polypeptides for intracellular delivery, polynucleotides encoding such osteoinductive polypeptides and protein transduction sequences, and methods of utilizing these fusion proteins to promote bone development and intervertebral disc regeneration in vivo.
- LIM mineralization protein splice variants 1 and 3 are osteoinductive, while LMP-2 does not appear to have such osteoinductive potential.
- a forty amino acid sequence corresponding to amino acids 94-133 of the amino acid sequence of human LMP-1 (hLMP-1) is common to both LMP-1 and LMP-3.
- the inventors therefore surmised that this unique region of the proteins might, in itself, have osteoinductive potential.
- Peptides comprising overlapping segments of this sequence were designed and used to test the inventors' hypothesis. Their results indicate that peptides derived from LMP-1 and LMP-3 have osteoinductive potential. When used in vivo, these peptides demonstrated the ability to induce bone formation.
- FIG. 6 indicates peptides which have demonstrated osteoinductive functionality when introduced into cells as part of the fusion protein of the present invention in the method of the present invention.
- Protein transduction polypeptides facilitate the uptake and subsequent expression of nucleic acid sequences or therapeutic proteins.
- they may be referred to alternately, and often interchangeably, as cell-permeable peptides, protein transduction domains, membrane transport sequences, and membrane-translocating peptides. They function to transport an attached peptide, polypeptide, or protein through the cell membrane into the interior of the cell in a receptor-independent manner.
- a fusion protein utilizing a protein transduction domain can comprise one or more peptides, polypeptides, or proteins operably linked to the protein transduction domain.
- such a fusion protein can comprise a protein transduction domain and at least one osteoinductive peptide, polypeptide, or protein, or combinations thereof.
- polypeptides can be used to transduce autologous, allogeneic, or xenogeneic cells or tissues of ectodermal, mesenchymal, or hematopoetic origin and infuse or implant them into the recipient to induce or contribute to the formation of new tissue.
- such polypeptides facilitate the uptake of proteins that can induce cells such as, for example, multipotent progenitor (stem) cells, to produce, for example, BMP-2, BMP-4, BMP-6, BMP-7, BMP-9, BMP-12, BMP-13, aggrecan, collagen type I, collagen type II, versican, lumican, fibromodulin, biglycan, and decorin.
- Effective amounts of polypeptides of the present invention are indicated in the experimental design and results disclosed herein, but may also be determined by one of skill in the art based upon the disclosure of effective amounts provided herein.
- Human LIM mineralization protein-1 (hLMP-1), one of a family of LMP proteins, is an intracellular regulatory protein that can enhance the efficacy of bone mineralization in vitro and in vivo.
- Human LMP-1 is so named because it possesses a characteristic structural motif composed of two special zinc fingers that are joined by an amino acid spacer.
- LIM mineralization protein splice variants and their uses have been described by the inventors in U.S. Pat. Nos. 6,300,127; 6,444,803; and 6,521,750. The sequences of LMP-1, LMP-2, and LMP-3 have also been disclosed in those patents. On Jul.
- a serotype 5 adenovirus (Ad5) has been employed for the delivery of LMPs to a variety of cells and tissues including cells derived from peripheral blood and bone marrow. (Boden, et al., “Adenoviral Delivery of LMP-1 Induces Consistent Spine Fusion”, 47 th Annual Meeting, Orthopaedic Research Society, San Francisco, Calif. (2001)).
- Ad5 virus utilizes a specific receptor (i.e., coxsackie adenovirus receptor or CAR), which is absent, or present in limited quantities, in these cells.
- CAR coxsackie adenovirus receptor
- LMPs and other osteoinductive proteins indicate that they have therapeutic potential in a variety of tissues, such as brain, spinal cord, peripheral nerve, bone, cartilage, intervertebral discs, connective tissue, tendons, and ligaments.
- Delivery of LMPs, for example, to a variety of tissues can be accomplished by delivery systems comprising, for example, collagen, collagen ceramic combinations, demineralized bone matrix, natural or synthetic polymers such as elastin, fibrin, polylactic acid, polyglycolic acid, polycaprolactone, polypropylene fumarate, polyvinyl alcohol, polyesters, polyethers, polyhydroxyls, and structural implants.
- Such matrices may be injectable, moldable, solid implants, structural implants, or combinations thereof.
- PTDs can be used to deliver functional osteoinductive proteins into cells and to effectively induce osteogenesis and proteoglycan synthesis.
- Such cell-permeable peptide import provides a method for delivering osteoinductive proteins into a variety of cell types.
- An 11 amino acid peptide initially derived from the HIV-1 TAT protein, was successfully used to deliver osteoinductive proteins into cells.
- the TAT peptide can be over-expressed in bacterial cells using the pTAT-HA vector.
- a recombinant human gene can be inserted into this vector in such a manner as to produce a fusion protein containing both the TAT peptide sequence as well as the gene product of interest.
- the PTD/osteoinductive polypeptide can be expressed in conjunction with a polyHis tag in order to facilitate isolation and purification of the fusion protein.
- the pTAT-HA vector and a purification protocol for TAT fusion proteins have been described previously by Nagahara, et al. ( Nature Medicine . Vol. 4) p. 1449-1452, December 1998).
- a peptide sequence as found in a variety of PTDs can facilitate entry into cells in a coxsackie-adenovirus receptor (CAR)-independent manner, thereby improving transduction efficiencies to target cells and subsequently lowering the required amounts of nucleic acid or protein needed to achieve the desired effect.
- PTD fusion proteins therefore provide a therapeutic tool that may be used to reduce the cost of therapy.
- a fusion protein of a protein transduction domain and an osteoinductive protein is provided.
- Osteoinductive proteins include, but are not limited to, LIM mineralization proteins (LMPs), bone morphogenetic proteins (BMP) and Smad proteins.
- LMPs LIM mineralization proteins
- BMP bone morphogenetic proteins
- Smad proteins Smad proteins.
- osteoinductive proteins osteoinductive polypeptides
- osteoinductive peptides may be used interchangeably to refer to either a peptide or polypeptide of varying length or a full-length protein with osteoinductive functionality.
- a fusion protein comprising a PTD and a LIM mineralization protein is provided as one embodiment of the invention.
- the fusion protein can comprise a PTD and one or more LIM mineralization proteins or polypeptides.
- Useful LIM mineralization proteins include, for example, LMPs as disclosed in U.S. Pat. Nos. 6,300,127; 6,444,803; and 6,521,750; as well as pending U.S. patent application Ser. No. 09/959,578, filed Apr. 28, 2000.
- the LMP is RLMP, HLMP-1, HLMP-1s, HLMP-2, HLMP-3, or a peptide derived therefrom.
- These peptides can include, for example, SEQ ID NO 1, SEQ ID NO 2, SEQ ID NO 3, SEQ ID NO 4, SEQ ID NO 5, SEQ ID NO 6, SEQ ID NO 7, or a polypeptide as in SEQ ID NO 8.
- the nucleotide sequence encoding the LIM mineralization protein preferably hybridizes under standard conditions to a nucleic acid molecule complementary to the full length of the following sequence:
- Standard hybridization conditions will vary with the size of the probe, the background and the concentration of the nucleic acid reagents, as well as the type of hybridization (in situ, Southern blot, or hybrization of DNA-RNA hybrids (Northern blot)).
- standard hybridization conditions are within the level of skill in the art. Methods include, for example, those described in U.S. Pat. No. 5,580,775 (Fremeau, et al.), Southern, J. Mol. Biol., 98:503 (1975), Alwine, et al., Meth. Enzymol., 68:220 (1979), and Sambrook, et al., Molecular Cloning: A Laboratory Manual, 2nd edition, Cold Spring Harbor Press, 7.19-7.50 (1989).
- One set of standard hybrization conditions involves pre-hybridizing a blot at 42° C. for 2 hours in 50% formamide, 5 ⁇ SSPE (150 nM NaCl, 10 mM Na H 2 PO 4 [pH 7.4], 1 mM EDTA [pH 8.0])15 ⁇ Denhardt's solution (20 mg Ficoll, 20 mg polyvinylpyrrolidone and 20 mg BSA per 100 ml water), 10% dextran sulphate, 1% SDS and 100 ⁇ g/ml salmon sperm DNA. A 32 P labeled cDNA probe is added, and further hybridizing continued for 14 hours.
- 5 ⁇ SSPE 150 nM NaCl, 10 mM Na H 2 PO 4 [pH 7.4], 1 mM EDTA [pH 8.0]
- Denhardt's solution (20 mg Ficoll, 20 mg polyvinylpyrrolidone and 20 mg BSA per 100 ml water
- 10% dextran sulphate
- the blot is washed twice with 2 ⁇ SSPE, 0.1% SDS for 20 minutes at 22° C., followed by a 1 hour wash at 65° C. in 0.1 ⁇ SSPE, 0.1% SDS.
- the blot is then dried and exposed to x-ray film for 5 days in the presence of an intensifying screen.
- a probe Under “highly stringent conditions”, a probe will hybridize to its target sequence if those two sequences are substantially identical. Techniques are known to those of skill in the art for determining the conditions under which only substantially identical sequences will hybridize while non-identical sequences will not.
- the term “protein” is intended to include mimetics and the term “amino acid” is intended to include L-form, D-form, and modified amino acids. These substitutions may be made by one of skill in the art, using the known structural similarities between the molecules.
- the amino acid sequence is also intended to include any peptide or protein sequence that may include additional amino acids either N-terminal or C-terminal to the listed sequence, or both.
- the term “osteoinductive protein” is intended to include variants or biologically active fragments of the polypeptide, as well as full-length proteins.
- alternate embodiments of the present invention include alternate DNA sequences encoding peptides containing the amino acid sequences as previously described.
- DNA sequences encoding peptides containing the claimed amino acid sequence include DNA sequences which encode any combination of the claimed sequence and other amino acids located N-terminal or C-terminal to the claimed amino acid sequence.
- amino acid and nucleic acid sequences may include additional residues, particularly N- or C-terminal amino acids or 5′ or 3′ nucleotide sequences, and still be essentially as set forth in the sequences disclosed herein, as long as the sequence confers osteoinductive potential upon the expressed polypeptide or protein.
- Additional nucleic acid bases may be added either 5′ or 3′ to the nucleotide sequence encoding the osteoinductive polypeptide, and may be combined with other DNA sequences, such as promoters, polyadenylation signals, additional restriction enzyme sites, multiple cloning sites, other coding segments, and the like. Therefore, overall length of such a polynucleotide may vary considerably.
- a “variant” of a polypeptide is not completely identical to the native protein.
- a variant of an osteoinductive polypeptide or protein for example, can be obtained by altering the amino acid sequence by insertion, deletion or substitution of one or more amino acids.
- the amino acid sequence of the polypeptide or protein can be modified, for example, by substitution to create a polypeptide having substantially the same or improved qualities as compared to the native polypeptide.
- the substitution may be a conserved substitution.
- a “conserved substitution” is a substitution of an amino acid with another amino acid having a side chain that is similar in polar/nonpolar nature, charge, or size.
- the 20 essential amino acids can be grouped as those having nonpolar side chains (alanine, valine, leucine, isoleucine, proline, phenylalanine, and tryptophan), uncharged polar side chains (methionine, glycine, serine, threonine, cystine, tyrosine, asparagine and glutamine), acidic side chains (aspartate and glutamate), and basic side chains (lysine, arginine, and histidine).
- conserveed substitutions might include, for example, Asp to Glu, Asn, or Gln; His to Lys, Arg or Phe; Asn to Gln, Asp or Glu; and Ser to Cys, Thr or Gly.
- Alanine for example, is often used to make conserved substitutions.
- variant polypeptides can be obtained by substituting a first amino acid for a second amino acid at one or more positions in the polypeptide structure in order to affect biological activity.
- Amino acid substitutions may, for example, induce conformational changes in a polypeptide that result in increased biological activity.
- a variant amino acid molecule of the present invention therefore, has less than one hundred percent, but at least about fifty percent, and preferably at least about eighty to about ninety percent amino acid sequence homology or identity to the amino acid sequence of a polypeptide comprising the amino acid sequence of LMP-1, LMP-2, LMP-3, SEQ ID NO 1, SEQ ID NO 2, SEQ ID NO 3, SEQ ID NO 4, SEQ ID NO 5, SEQ ID NO 6, SEQ ID NO 7, or a polypeptide as in SEQ ID NO 8.
- the amino acid sequence of the variant osteoinductive polypeptide or protein corresponds essentially to the native osteoinductive polypeptide or protein amino acid sequence.
- “corresponds essentially to” refers to a polypeptide sequence that will elicit a similar biological and enzymatic activity to that generated by an osteoinductive polypeptide or protein comprising LMP-1, LMP-2, LMP-3, SEQ ID NO 1, SEQ ID NO 2, SEQ ID NO 3, SEQ ID NO 4, SEQ ID NO 5, SEQ ID NO 6, SEQ ID NO 7, or a polypeptide as in SEQ ID NO 8., such activity being at least about 70 percent that of the native osteoinductive protein, and more preferably greater than 100 percent of the activity of the native osteoinductive protein.
- a variant of the osteoinductive protein may include amino acid residues not present in a corresponding osteoinductive protein comprising LMP-1, LMP-2, LMP-3, SEQ ID NO 1, SEQ ID NO 2, SEQ ID NO 3, SEQ ID NO 4, SEQ ID NO 5, SEQ ID NO 6, SEQ ID NO 7, or SEQ ID NO 8, or may include deletions relative to the osteoinductive protein comprising LMP-1, LMP-2, LMP-3, SEQ ID NO 1, SEQ ID NO 2, SEQ ID NO 3, SEQ ID NO 4, SEQ ID NO 5, SEQ ID NO 6, SEQ ID NO 7, or SEQ ID NO 8.
- a variant may also be a truncated “fragment,” as compared to the corresponding protein comprising LMP-1, LMP-2, LMP-3, SEQ ID NO 1, SEQ ID NO 2, SEQ ID NO 3, SEQ ID NO 4, SEQ ID NO 5, SEQ ID NO 6, SEQ ID NO 7, or SEQ ID NO 8., the fragment being only a portion of the full-length protein or polypeptide.
- Bone morphogenetic proteins are members of the TGF- ⁇ superfamily of proteins. BMPs have been shown to induce ectopic bone or cartilage formation. According to the invention, a fusion protein of a PTD and a bone morphogenetic protein is also provided. BMPs include, for example, BMP-2, BMP-3, BMP-3b, BMP-4, BMP-5, BMP-6, BMP-7, BMP-8, BMP-9, BMP-10, BMP-11, BMP-12, BMP-13, BMP-14, BMP-15, GDF-1, GDF-3, GDF-8 and GDF-9. Bone morphogenetic proteins BMP-2, BMP-4, BMP-5, BMP-6, BMP-7, BMP-8, or BMP-9 can be especially useful in the method of the present invention.
- Smad proteins are intracellular proteins that mediate signaling from receptors for extracellular TGF-beta-related factors (Heldin. et al., “TGF- ⁇ Signalling from Cell Membrane to Nucleus through SMAD Proteins”, Nature , Vol. 390 (1997)). Smad proteins can be activated (i.e., phosphorylated) by the binding of a BMP to its receptor. Upon activation, the Smad proteins translocate to the nucleus where they regulate gene expression. A fusion protein of a PTD and a Smad protein is also provided in the present invention. Smad-1, Smad-2, Smad-3, Smad-4, Smad-5, Smad-6, Smad-7 or Smad-8 can be especially useful for promoting osteoinduction when delivered as a fusion protein with a protein transduction domain as in the present invention.
- the protein transduction domain according to the invention can be any peptide, mimetic, or peptide nucleic acid (PNA) sequence that can traverse the plasma membrane of a cell to deliver an attached or accompanying protein, peptide, or nucleic acid to the interior of the cell.
- PNA peptide nucleic acid
- the inventors have demonstrated that osteoinductive proteins can be delivered intracellularly (as a fusion protein moiety, for example) without impairing their ability to promote osteoinduction and proteoglycan synthesis.
- PTDs include, for example, polypeptides derived from the Drosophila homeotic transcription factor Antennapedia (Antp), the herpes simplex virus (HSV) protein VP22, signal peptide sequences from growth factors such as Kaposi's fibroblast growth factor (K-FGF) (Lin, et al., J. Biol. Chem ., Vol. 270, p. 14255-14258, 1995) a membrane translocation sequence derived from the K-FGF signal peptide sequence (Rojas, et al, Nat. Biotech ., Vol. 16, p.
- K-FGF Kaposi's fibroblast growth factor
- HIV-1 transcriptional activator TAT human immunodeficiency virus-1 transcriptional activator TAT
- PTDs are disclosed in U.S. Pat. No. 5,652,122, and in Schwarze. et al., “Protein Transduction: Unrestricted Delivery into all Cells”, Trends in Cell Biology , Vol. 10 (2000). The inventors have found the HIV-TAT PTD to be especially useful in the present invention.
- a nucleic acid comprising a nucleotide sequence encoding a fusion protein operably linked to a promoter, wherein the fusion protein comprises a protein transduction domain (PTD) and an osteoinductive protein, is also provided.
- the nucleic acid can be part of a vector (e.g., an expression vector such as a plasmid).
- Osteoinductive proteins can include, for example, LIM mineralization proteins, bone morphogenetic proteins, Smad proteins, and osteoinductive peptides and polypeptides derived therefrom. Examples of osteoinductive peptides and polypeptides include SEQ ID NO 1, SEQ ID NO 2, SEQ ID NO 3, SEQ ID NO 4, SEQ ID NO 5, SEQ ID NO 6, SEQ ID NO 7, and SEQ ID NO 8.
- At least one osteoinductive protein can be delivered into a cell via transduction wherein a fusion protein comprising a protein transduction domain (PTD) and an osteoinductive protein is contacted with the cell so that the fusion protein is delivered into the cell, the delivery being facilitated by the protein transduction domain or cell-permeable peptide
- PTD protein transduction domain
- the cells into which the osteoinductive proteins can be delivered include, for example, osseous (i.e., bone forming) and non-osseous cells.
- Such cells may include, for example, buffy coat cells, stem cells (e.g., mesenchymal stem cells, multipotent and pluripotent stem cells), intervertebral disc cells (e.g., cells of the annulus fibrosus and cells of the nucleus pulposus), mesenchymal cells, hematopoietic cells, endothelial cells and muscle cells.
- stem cells e.g., mesenchymal stem cells, multipotent and pluripotent stem cells
- intervertebral disc cells e.g., cells of the annulus fibrosus and cells of the nucleus pulposus
- mesenchymal cells hematopoietic cells
- endothelial cells endothelial cells and muscle cells.
- Stem cells can be derived from autalogous or allogen
- Cells transduced with or expressing a fusion protein of a protein transduction domain (PTD) and an osteoinductive protein are also provided.
- Such cells may include, but are not limited to, buffy coat cells, stem cells (e.g., mesenchymal stem cells and pluripotential stem cells), intervertebral disc cells (e.g., cells of the annulus fibrosus and cells of the nucleus pulposus), mesenchymal cells, hematopoietic cells, endothelial cells and muscle cells.
- Cells containing a fusion protein of a PTD and an osteoinductive protein as described herein can be implanted into the body of a mammal to induce bone formation.
- a Conjugate of a PTD and a nucleic acid comprising a nucleotide sequence encoding an osteoinductive protein is also provided.
- the PTD/nucleic acid conjugate can be used to direct over-expression of an osteoinductive protein to promote bone formation or disc regeneration, for example.
- Osteoinductive proteins encoded by the nucleotide sequence can include, but are not limited to, LMPs, BMPs, and Smad proteins. Methods for chemically linking peptides to nucleic acids are known in the art. One such method is described in U.S. Pat. No. 5,652,122.
- the nucleic acid can be in the form of an expression vector comprising a nucleotide sequence encoding an osteoinductive protein operably linked to a promoter.
- Methods of the present invention can be used to induce the expression of one or more bone morphogenetic proteins or transforming growth factor- ⁇ proteins in a cell as described in copending U.S. patent application Ser. No. 10/382,844, filed Mar. 7, 2003.
- the expression of one or more proteins selected from the group consisting of BMP-2, BMP-4, BMP-6, BMP-7, TGF- ⁇ 1 and combinations thereof can be induced by contacting a cell with a fusion protein comprising a PTD and an osteoinductive protein according to the invention.
- cells which over-express one or more proteins selected from the group consisting of BMP-2, BMP4, BMP-6, BMP-7, TGF- ⁇ 1 and combinations thereof are also provided according to the invention.
- the cell can be any somatic cell including, but not limited to, a stem cell, a buffy coat cell, a bone marrow cell, a peripheral blood cell or a fat cell.
- the cell can be a stem cell derived from autologous or allogeneic tissue.
- Stem cells can provide a source of cells from which to generate osteoblasts. These cells may be isolated at various stages of differentiation and induced to differentiate in specific lineage pathways. The cells may be used to treat bone diseases such as osteoporosis or osteogenesis imperfecta, as well as non-healing fractures. Core binding factor alpha 1 (Cbfa1) has been demonstrated to be necessary for osteogenesis. BMP-2, BMP-4, and BMP-7, which are known to induce osteoblast differentiation, up-regulate Cbfa1 expression. BMP-8 and Smad-3 are up-regulated during osteoblast differentiation. Activation of TGF-beta/BMP-Smad signaling has been shown to promote Cbfa1 expression, and osteoblast differentiation.
- Cbfa1 Core binding factor alpha 1
- the present invention provides fusion proteins comprising functional BMPs, LMPs, Smad proteins, or a combination thereof, for example, to promote osteoblast differentiation in cells such as human bone marrow-derived mesodermal progenitor cells.
- Suitable cells may include, for example, multipotent cells such as those described by Jiang, et al. ( Nature , Vol. 418, p. 41-49, 2002).
- Administration of suitable osteoinductive proteins or polypeptides, or combinations thereof, can be performed ex vivo before implantation of the cells, or in vivo following implantation or injection.
- osteoinductive proteins of the present invention can be injected at a target site so that they can be delivered to the interior of nearby cells via a PTD or cell-permeable peptide, for example.
- a PTD or cell-permeable peptide for example.
- an implant comprising a carrier in combination with a PTD/osteoinductive polypeptide may be used.
- Implants may contain reservoirs in which to place the PTD/osteoinductive polypeptide for release into the surrounding tissue, or may comprise a porous composition that has been soaked in a solution containing one or more PTD/osteoinductive polypeptide constructs.
- Hydrogels, time-release capsules or spheres, liposomes, microspheres, nanospheres, biodegradable polymers, or other such drug delivery systems may also be employed to deliver peptides and proteins of the present invention to target cells and tissues.
- U.S. Pat. No. 6,475,516 (DiCosmo, et al.), for example, provides hydrogels loaded with liposomal therapeutic agents such as antibiotics, the hydrogels being covalently bonded to the surface of an in-dwelling medical device such as an implant.
- a hallmark of disc degeneration is the decreased production of proteoglycans in the disc, especially sulfated-glycosaminoglycans (sGAG) and aggrecan.
- sGAG sulfated-glycosaminoglycans
- aggrecan the major proteoglycan of the intervertebral disc
- restoration of normal proteoglycan production of the intervertebral disc may be critically important in any biological treatment of intervertebral disc degeneration.
- LMP-1 over-expression or intracellular administration increases disc cell proteoglycan production in vitro and-in vivo.
- LMP-1 over-expression induces the upregulation of BMP-2 and BMP-7 mRNA in vitro and in vivo.
- Noggin which specifically inhibits these BMP-2 and BMP-7, inhibits proteoglycan upregulation by AdLMP-1, indicating that LMP-1 induced upregulation of proteoglycan is mediated by the upregulation of BMPs.
- LMP-1 administration via gene therapy or protein therapy e.g., delivery by PTD conjugates therefore can be used to stimulate proteoglycan production in discs and play a therapeutic role in disc regeneration.
- Cytokines such as TGF- ⁇ 1, IGF-1, and EGF have been shown to stimulate intervertebral disc cell mitosis and, to some extent, proteoglycan production.
- Other cytokines such as BMP-2 and BMP-7 have also been shown to be effective in stimulating proteoglycan production. Because cytokines are small water soluble molecules, however, they rapidly diffuse away from the intervertebral disc or become inactivated by other regulatory factors.
- LIM Mineralization Protein-1 LMP-1 is an intracellular regulatory molecule that is known to induce the secretion of multiple different BMPs from leukocytes and osteoblasts.
- Suitable osteoinductive peptides include, for example, SEQ ID NO 1, SEQ ID NO 2, SEQ ID NO 3, SEQ ID NO 4, SEQ ID NO 5, SEQ ID NO 6, SEQ ID NO 7, or a polypeptide as in SEQ ID NO 8.
- NcoI restriction site was added to the 5′ end of hLMP-1 by utilizing pcDNA3.1/hLMP-1 as the template for PCR with the following primers: Fwd: 5′-CCATGGAflCCflCAAAGTAGTGC-3′ Rev: 5′-CAGGGCGGGCGGCTGGTAG-3′
- the reaction was performed at: 95° C. for 2 Min.[95° C., 30 sec; 66° C., 30 sec; 72° C., 1 mm] ⁇ 25, and 72° C. 10 mm.
- the PCR product was cloned into PCRII-TOPO vector (Invitrogen) and appropriate clones were identified by sequencing.
- Construction of the (His) 6 TAT-LMP vector was accomplished by restriction endonuclease digestion of plasmid clones with NcoI and ClaI, and purification of the resulting product by agarose gel electrophoresis and electroelution.
- the full-length hLMP-1 sequence was isolated by restriction digest of the pcDNA3.1/hLMP-1 vector with ClaI and EcoRI, and purification of the resulting product by agarose gel electrophoresis and electroelution.
- the pTAT-HA-vector was also subjected to restriction digestion with NcoI and EcoRI, and the resulting linearized vector was purified by agarose gel electrophoresis and electroelution. Products were then ligated by standard procedures overnight at 16° C.
- Ligation products were transfected into BL21 (DE3) competent cells and suitable clones were identified by restriction analysis.
- the lysate was clarified by centrifugation (10000 ⁇ g) and the resulting supernatant applied to a Ni 2+ sepharose affinity column (Invitrogen) under gravity flow conditions.
- the column was washed (20 mM PO 4 buffer, pH 6.0, 8 M Urea, 250 mM NaCl, 20 mM Imidazole) and then bound proteins eluted (20 mM PO 4 buffer, pH 4.0, 8 M Urea, 500 mM NaCl).
- Eluate was subjected to anion exchange chromatography (Hitrap Q HP, 5 mL, Pharmacia) using a linear gradient (Buffer A: 20 mM sodium carbonate, pH 11, 8 M Urea; Buffer B: 20 mM sodium carbonate, pH 11, 8 M Urea, 2 M NaCl) from 0% Buffer B to 100% Buffer B (40 mm @ 5 mL/min). Eluted fractions (5 mL) were analyzed for the presence of hLMP-1 by SDS-PAGE and Western blot analyses.
- Lyophilized fractions were resuspended into 40 mM KOH to (Stock Solution; 1.0 ⁇ M).
- Human buffy coat cells were prepared as described in Viggeswarapu, et al., J. Bone Joint Surg ., Vol. 83(3), p. 364 (2001). These cells were mixed with 5 ⁇ L of (His) 6 TAT-LMP fusion protein in alpha MEM (Gibco) and incubated for 30 min.@ 37° C.
- radiography revealed a high level of mineralized bone formation conforming to the form of the original collagen discs or sheets containing LMP-1 transfected human buffy coat cells. No mineralized bone formation was observed in the control, and the original collagen discs or sheets appeared to be undergoing absorption. Histology revealed new bone trabeculae lined with osteoblasts in the LMP-1 transduced implants, whereas no bone was seen, and the carrier was partially resorbed, in the controls.
- Protocols were essentially as described above. Peptides were applied to 4 separate implants (3 for rabbit), 250 microliters per disc, 6M/ml. Implants comprised collagen discs. Implants were placed within the chest of Harlan athymic rats or New Zealand White rabbits. Dose ranges tested were 5 nM, 10 nM, 12.5 nM, 15 nM, 17.5 nM, 20 nM, 22.5 nM, and 25 nM. Results are shown in FIG. 6 .
- a direct ELISA method was used to quantiate the levels of BMP-2, 4, 6, and 7 in the media.
- a molecule which specifically blocks BMP-2, 4, 6, and 7 activities was added to AdLMP-1 treated cells at different concentrations.
- Lumbar discs were injected with either AdLMP-1 (experimental) or an adenovirus carrying a marker gene (AdLacZ—control) at three different doses (106, 107, and 108 pfu/disc). Three weeks later the injected discs were harvested and the mRNA level of total LMP-1 (endogenous), over-expressed LMP-1, aggrecan, BMP-2, and BMP-7 were measured.
- AdLMP-1 at a multiplicity of infection (MOI) of 25 was sufficient to induce the maximal level of sGAG upregulation.
- MOI 25 A period of 6 days in monolayer culture was required to reach the maximal level of sGAG upregulation after AdLMP-1 treatment (MOI 25).
- Aggrecan mRNA increased by 2 times compared to control.
- BMP-2 and BMP-7 mRNA levels increased significantly to 3.0+0.2 and 2.8+0.3 times that of controls (p ⁇ 0.01), respectively.
- BMP-4 and BMP-6 mRNA levels were unchanged.
- BMP-2 and BMP-7 protein levels in the media were increased significantly (p ⁇ 0.01) compared to control.
- BMP-4 and BMP-6 protein levels were not elevated.
- Noggin at 3200 ng/ml completely blocked the upregulation of proteoglycan by AdLMP-1. Endogenous levels of LMP-1 mRNA were detected in lumbar nucleus pulposus.
- In vivo discs injected with 107 pfu/disc of AdLMP-1 had a significantly elevated level of LMP-1, BMP-2, and BMP-7 mRNA levels compared to control.
- a replication deficient type 5 adenovirus carrying the cDNA for the human LMP-1 gene was used (AdLMP-1).
- Monolayer culture experiments with SD annulus cells were (carried out to determine the relationship between virus dose and over-expressed LMP-1 mRNA expression using realtime PCR method using a primer that is specific for only the virally delivered LMP-1 cDNA.
- Monolayer culture experiments with SD annulus cells were performed to determine the relationship between virus dose and sGAG production. The sGAG levels were measured with a DMMB method.
- the optimal dose of AdLMP-1 was defined as the lowest dose which led to the plateau level of sGAG production.
- the virus was administered by delivery in 10 microliters of phosphate buffered saline through a 30G Hamilton syringe. After 3 weeks, nucleus pulposus tissue from the injected lumbar discs was harvested. Nucleus tissues from two rabbits were pooled into either control or experimental disc groups to obtain sufficient mRNA for further analysis. Reverse transcription and real-time PCR were used to quantitate the mRNA levels of total LMP-1, BMP-7, and aggrecan. The primers for total LMP-1 were designed to identify both endogenous and over-expressed LMP-1.
- AdLMP-1 AdLMP-1 at three different doses (10 6 , 10 7 , 10 8 pfu) and AdGFP at a single dose (10 7 pfu) were administered.
- All the discs from each animal were injected with a single dose of virus instead of alternating virus type as in the previous experiment.
- Eight NZW rabbits (3-4 kg) were used, two rabbits for each of the four virus groups. The rabbits were euthanized three weeks later and the nucleus pulposus was harvested. The harvested tissue from within each treatment group was pooled, mRNA isolated and used to generate corresponding cDNA. Real-time PCR was used to quantitate the mRNA levels of total LMP-1, over-expressed LMP-1, BMP-2, BMP-7, and aggrecan.
- over-expressed LMP-1 mRNA The relative amounts of over-expressed LMP-1 mRNA at 12 hours after virus treatment at different doses (MOI 0, 10, 25, and 50) were normalized to the lowest detectable level of over-expressed LMP-1 mRNA (AdLMP-1 MOI 5). Increasing the dose of AdLMP-1 resulted in statistically significant increases in over-expressed LMP-1 mRNA as compared to MOI 5. No detectable levels of over-expressed LMP-1 mRNA could be found in the untreated control or the AdLacZ control groups, indicating that AdLMP-1 induced over-expression of LMP-1 in annulus cells in a dose dependent manner.
- the sGAG concentration in the culture media from annulus cells was determined 6 days after treatment with AdLMP-1 at different doses.
- the sGAG concentration in the culture media on day 6 is a measure of the total sGAG produced by the cells over the three-day time period between media change and the sGAG measurement, and therefore is a measure of the production rate of sGAG during that time period. Data is expressed as a ratio between treated and untreated controls.
- Administration of LMP-1 via AdLMP-1 at MOI 25
- a time-course experiment was carried out to determine the effect of varying the length of the experiment after treatment with AdLMP-1 at MOI 25.
- Annulus cells were treated with LMP-1 (AdLMP-1 at MOI 25), and the production of sGAG over three day increments were measured. The results were normalized by DNA content at each time point and expressed as a ratio to untreated controls from the same time point.
- the sGAG level was increased to 1.6 ⁇ 0.2 p ⁇ 0.01) on day 3, to 2.9 ⁇ 0.1 (p ⁇ 0.01) on day 6, and to 2.8 ⁇ 0.1 (p ⁇ 0.01) on day 9. No increase in sGAG level was noted between day 6 and day 9, indicating that a pleateau level was achieved by day 6.
- aggrecan is the predominant proteoglycan of the intervertebral disc
- aggrecan core protein mRNA levels were measured 6 days after treatment with AdLMP-1. Quantitative real-time PCR methods were used and the data are presented as a ratio to untreated controls. After AdLMP-1 treatment (MOI 25), aggrecan mRNA level was 2.1 ⁇ 0.1 (p ⁇ 0.01) times that of controls. After AdLacZ treatment (MOI 25) aggrecan mRNA level was unchanged, 1.0 ⁇ 0.16 times that of controls.
- Alginate provides a three-dimensional matrix for cells that is important for maintenance of chondrocytic phenotype in long term in vitro cultures.
- Annulus cells grown in monolayer were treated with AdLMP-1 at MOI 25 then transferred to alginate culture 24 hours later. The cells were cultured for periods of 1, 2, and 3 weeks.
- the sGAG level in the AdLMP-1 group was 1.5 ⁇ 0.06 (p ⁇ 0.01) times that of untreated control ( FIG. 5 ).
- the sGAG in the AdLMP-1 treated group increased to 2.9+0.3 (p ⁇ 0.01) times that of untreated controls. This difference was maintained at 3 weeks; the sGAG level in the AdLMP-1 treated group was 2.9 ⁇ 0.1 (p ⁇ 0.01) times that of controls. This indicated that AdLMP-1 was effective in maintaining increased sGAG accumulation in alginate for at least 3 weeks in culture.
- BMP-2 mRNA was upregulated early, reaching a statistically significant (p ⁇ 0.01) increase at 12 hours after LMP-1 treatment.
- BMP-2 mRNA increase reached a plateau level by day 3.
- BMP-7 mRNA was upregulated later than BMP-2, reaching statistically significantly increase at day 3 (p ⁇ 0.01) and day 6 (p ⁇ 0.01). Neither BMP-4 nor BMP-6 mRNA levels were significantly different from those of untreated controls.
- Endogenous levels of aggrecan, BMP-7, and LMP-1 mRNA in the control discs were detected in the nucleus pulposus. Endogenous mRNA levels were used to calculate the increase in aggrecan, BMP-7, and LMP-1 mRNA in the AdLMP-1 injected discs. Discs injected with AdLMP-1 expressed 830% higher levels of total LMP-1 mRNA than the discs injected with AdGFP. Administration of LMP-1 via AdLMP-1 produced an 1100% increase in the BMP-7 mRNA level over control (p ⁇ 0.05). Aggrecan mRNA level was increased by 66% over control (p ⁇ 0.05).
- LMP-1 to intervertebral disc cells resulted in an increase in sGAG production and an increase in aggrecan mRNA levels.
- LMP-1 administration produced an increase in the mRNA and protein levels of BMP-2 and BMP-7 in vitro, and the effect of LMP-1 administration on upregulation of proteoglycan production could be blocked by administration of the BMP inhibitor noggin.
- intervertebral disc tissue from the lumbar spine and tail were harvested in under sterile conditions. Annulus fibrosus and nucleus pulposus were separately dissected and diced.
- the intervertebral disc tissue was placed in Dulbecco's modified Eagle's medium and Ham's F12 medium (DMEM/F-12; GIBCO BRL, Grand Island, N.Y., U.S.A.) containing 100 unit/ml penicillin and 100 mg/ml streptomycin.
- the intervertebral disc tissue was treated with 0.2% pronase (Sigma Chemical, St.
- the replication deficient type 5 Adenovirus containing the human LMP-1 cDNA driven by a CMV promoter was used as the experimental virus.
- the control virus consisted of a similar replication deficient type 5 adenovirus containing the lacZ cDNA.
- the cells were subcultured into 6-well plates at 400,000 cells per well. Three days later, the cells were treated with adenovirus containing the cDNA for either the human LMP-1 gene (AdLMP-1) or the LacZ gene (AdLacZ). Cell number was determined at day 0 by counting a control well using a hemocytometer. The viral dose was expressed as a multiplicity of infection (MOI), the number of plaque-forming unit (pfu) per cell. This is essentially the number of recombinant adenoviral plaque-forming units to which a single intervertebral disc cell was exposed. The cultured cells were treated for thirty minutes at 37° C.
- MOI multiplicity of infection
- pfu plaque-forming unit
- AdLMP-1 or AdLacZ in 300 ml of DMEM/F-12 with 0% FBS at different MOIs (o, 10, 25, 50) as designated in each experiment. Then the culture volume was raised to 2.0 ml with DMEM/F-12 medium containing 1% FBS, 100 unit/ml penicillin, 100 mg/ml streptomycin, 2 mM L-glutamine and 50 mg/ml Vitamin C. The medium was changed every 3 days during the experiment.
- the sulfated-glycosaminoglycan (sGAG) content of the culture media was assayed using the 1,9-dimethylmethylene blue (DMMB) method.
- the culture media 2 ml was centrifuged (5000 ⁇ G for 30 minutes) to concentrate the sGAG using the Centricon YM-50 centrifugal filter (Millipore Co., Bedford, Mass., U.S.A.).
- the sample solution (20 ml) were mixed gently with 200 ml DMMB dye solution in a 96-well microtiter plate, and the optical density (OD) was checked immediately at 520 nm wavelength filter.
- a standard curve was constructed using serial dilutions of chondroitin sulfate (Sigma Chemical, St. Louis, Mo., U.S.A.). Total sGAG in the media were normalized by DNA content and presented as a ratio to the untreated control.
- the cell number was determined by the DNA content of each well, and DNA content was measured with a Hoechst dye 33258 (Polysciences, Warrington, Pa., U.S.A.) method, as previously described. Cultured cells were removed from the plate by exposure to papain (10 units/ml). Cells were then pelleted and incubated at. 60° C. for 3 hours. A twenty microliter aliquot of the papain digest was mixed with 200 ml of Hoechst dye 33258 solution in a 96-well fluoroplate.
- Hoechst dye 33258 Polysciences, Warrington, Pa., U.S.A.
- Emission and excitation spectra were measured in Luminescence Spectrometer LS 50B (Perkin-Elmer, Wellesly, Mass., U.S.A.) at 456 nm and 365 nm, respectively. Standard curves were generated at the time of each measurement using known concentrations of calf thymus DNA (Sigma Chemical, St. Louis, Mo., U.S.A.).
- Alginate bead cultures are useful for maintaining chondrocytic phenotype in long term cultures. This method was to determine the effect of AdLMP-1 in three week cultures. The cells were treated in monolayer cultures as described above. One day later, the cells were released by trypsinization and washed 2 times with media. The isolated cells were resuspended in 0.6% low-viscosity sterile alginate (Sigma Chemical, St. Louis, Mo., U.S.A.) solution at 600,000 cells/ml. The cells were dispensed into a 0.102M CaCl+0.15M NaCl solution in a dropwise fashion through a 21-gauge needle attached to 10-ml plastic syringe in order to form the alginate beads.
- 0.6% low-viscosity sterile alginate Sigma Chemical, St. Louis, Mo., U.S.A.
- the newly formed beads (containing approximately 12,000 cells/bead) were washed three times with sterile 0.9% NaCl solution followed by two washes with DMEM/F-12.
- the beads containing the annulus fibrosus cells were separately cultured in 6 wells plate with DMEM/F-12 medium containing 1% FBS, 100 unit/ml penicillin, 100 mg/ml streptomycin, 2 mM L-glutamine and 50 mg/ml Vitamin C.
- the media was changed every two days for different time periods (1, 2, and 3 weeks).
- the alginate beads were dissolved in 350 ml sodium citrate buffer (55 mmol/L Na-citrate, 50 mmol/L EDTA, 150 mmol/L NaCl, pH7.4). Cells were pelleted with centrifugation and the sGAG content in the dissolved solution was measured with the DMMB method described above. The sGAG content that remained the cell pellet was negligible compared to that in the suspension. The results were described as fold increase over untreated control group using sGAG of dissolved solution.
- Real-time PCR was used to determine mRNA levels of BMP-2, BMP-4, BMP-6, BMP-7, and over-expressed LMP-1 in a quantitative fashion.
- the primers for all of the genes were validated by determining the product size on an agarose gel and by DNA sequencing the amplicon. 18S levels were determined in each sample to use as an internal control.
- RNA of each sample was extracted by a single-step method using a guanidium thiocyanate-phenol-chloroform technique. The concentration of the isolated RNA was determined with a spectrophotometer (DU-500; Beckman, Fullerton, Calif., U.S.A.) at 260 nm wavelength. The RNA was treated with DNAse 1 (Ambion, Inc. Texas, U.S.A.) to remove DNA contamination of the samples.
- Reverse transcription was carried out in 40 ml volume with 2 mg of total RNA; 30U Avian Myeloblastosis virus reverse transcriptase (Promega, Madison, Wis., U.S.A.); 5 mM of MgCl 2 ; 60 U/ml of RNAsin (Promega, Madison, Wis., U.S.A.); 1 mM of each deoxyadenosine triphosphate (dATP), deoxycytidine triphosphate (dCTP), deoxyguanidine triphosphate (dGTP), deoxythymidine triphosphate (dTTP); and 1 mg oligo(dT) 15 primer for 45 minutes at 42° C.
- dATP deoxyadenosine triphosphate
- dCTP deoxycytidine triphosphate
- dGTP deoxyguanidine triphosphate
- dTTP deoxythymidine triphosphate
- oligo(dT) 15 primer for 45 minutes at 42° C.
- PCR was performed for 30 cycles (95° C., 30′′; 62° C., 30′′; 72° C., 45′′) with Amplitaq® DNA polymerase. To confirm the absence of DNA contamination, RNA samples treated without reverse transcriptase were also subjected to PCR: the absence of PCR product confirmed the lack of DNA contamination.
- Real-time PCR has been reported to be a rapid, reliable, and reproducible method for quantitative detection of specific mRNAs.
- a real-time PCR method using SYBR® Green Real-Time PCR Kit (Applied Biosystems, Foster City, Calif., U.S.A.) was used to perform quantitative mRNA analysis of BMP-2, BMP-4, BMP-6, BMP-7, and aggrecan.
- Twenty-five microliters (25 ml) of reaction volume included 5 ml of cDNA, 3.75 picomole of each primer (BMP-2,-4,-6,-7 and 18S), and 12.5 ml of SYBR® Green master mix (2 ⁇ , Biorad, Hercules, Calif., U.S.A.).
- Real-time PCR was performed with the following 3 step protocol; step 1: 50° C. for 2 minutes, step 2: 95° C. for 10 minutes, and step 3: (95° C. for 15 seconds, 60° C. for 1 minute) ⁇ 45 cycles using the GeneAmp®; 5700 Sequence Detection system (Applied Biosystems, Foster City, Calif., U.S.A.).
- step 1 50° C. for 2 minutes
- step 2 95° C. for 10 minutes
- step 3 (95° C. for 15 seconds, 60° C. for 1 minute) ⁇ 45 cycles using the GeneAmp®; 5700 Sequence Detection system (Applied Biosystems, Foster City, Calif., U.S.A.).
- step 3 the PCR products were subjected to a dislocation curve analysis. Threshold cycles (Ct) of each reaction were standardized according to 18S using the comparative- ⁇ Ct method, as described previously.
- Standard curves of BMPs were constructed using increasing concentrations (0.1 ng/100 ⁇ L per well to 1000 ng/100 ⁇ L per well) of human BMP 2, 4, 6, and 7 (Genetics Institute, Cambridge, Mass.) dissolved in 0.05 mol/L bicarbonate buffer. One hundred microliters of the samples were added to each well in triplicate. After incubating overnight at 4° C., the plates were washed with 0.01 M phosphate-buffered saline with 0.5% Tween 20 (PBST) three times and unreacted sites were blocked with 1% bovine albumin (Sigma, ST. Louis, Mo.) at room temperature for 1 hour.
- PBST phosphate-buffered saline with 0.5% Tween 20
- Noggin is a glycoprotein that binds to BMP-2, 4, 6, and 7 in a highly specific manner and prevents these BMPs from activating their cognate receptors.
- a form of mouse noggin (noggin-FC Sigma Chemical, St. Louis, Mo., U.S.A.) was used in experiments to determine the effect of specifically blocking BMPs after AdLMP-1 treatment.
- Noggin at different concentrations 100, 200, 400, 800, 1600 and 3200 ng/ml
- MOI 25 AdLMP-1
- the conditioned media were assayed to examine sGAG production using the DMMB method described above. Results indicated that LMP-1 effects could be blocked by administration of Noggin, demonstrating that LMP-1 activity is, in part, related to its induction of BMPs.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Zoology (AREA)
- Biophysics (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Toxicology (AREA)
- Insects & Arthropods (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Virology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
Description
- This application claims the benefit of U.S. provisional application No. 60/456,551, filed Mar. 24, 2003.
- The present invention relates generally to osteoinductive proteins and methods for the delivery of those proteins into cells. More specifically, the invention relates to osteoinductive proteins such as LIM mineralization proteins (LMPs), bone morphogenetic proteins (BMPs) and Smad proteins, conjugates of such osteoinductive proteins with protein transduction domains (PTDs), conjugates of PTDs and nucleic acids comprising nucleotide sequences encoding osteoinductive proteins, and to the transduction of these conjugates into cells. Furthermore, the invention relates to the use of PTD/osteoinductive protein conjugates to promote bone growth and disc regeneration.
- Tissue regeneration is an important component of the healing process subsequent to disease, trauma, or surgery. In situations where disease or trauma produces bone defect, for example, or where a surgical procedure such as insertion of an autograft or allograft, bone bridge, or bone fusion is used to correct a bone defect, bone regeneration is a central goal of recovery. It is not, however, a goal that is always or easily achieved and much research has been devoted to newer and more effective ways to promote tissue repair and regeneration.
- Elimination of joint motion by creation of a bone bridge is a common orthopedic strategy for the treatment of degenerative spine and joint disorders. Failure of spine fusion can occur in as many as forty-five percent of the patients who undergo the procedure, leaving them with continued pain, repeated surgeries, medical costs, and overall therapeutic failure.
- Intracellular and extracellular osteoinductive proteins promote bone growth and repair and constitute potential targets for therapeutic use. Such proteins include the bone morphogenetic proteins and the LIM mineralization proteins. BMPs have been shown to stimulate bone growth in vivo and LMPs, particularly LMP-1 and LMP-3, have a more upstream effect on osteoinduction, as evidenced by the fact that inhibition of LMP-1 expression blocks nodule formation that would normally be stimulated by glucocorticoids or BMP-6. Since they are considered “extracellular” proteins, acting via interaction with cell surface receptors, very high doses of bone morphogenetic proteins are required to achieve consistent effects in humans. Since the manufacturing costs of BMPs is generally high, this can mean that the cost of therapy is prohibitive. Therefore, although BMPs have demonstrated efficacy and are a viable therapeutic aid to osteoinduction, it would be beneficial to develop an alternate therapy that might be more cost-effective and possibly even more therapeutically effective.
- Delivery of LMPs to the intracellular environment provides an attractive therapeutic regimen. This can be accomplished by transfection of cells with plasmids comprising a nucleotide sequence encoding a LIM mineralization protein, or can be done by infection of target cells with a viral vector carrying the nucleotide sequence of LMP. Each of these techniques has limitations, however. Plasmid transfection generally requires that cells be isolated for transfection and then implanted after transfection. Viral delivery generally requires that the appropriate receptor be located on the surface of the target cell in order to facilitate viral entry into the cell.
- There is tremendous potential for the use of osteoinductive proteins and peptides, particularly for the use of those proteins and peptides that act via an intracellular mechanism. What is needed is a method of delivery of effective intracellular osteoinductive proteins and peptides into cells.
- The present invention provides a method of producing a cell-permeable osteoinductive polypeptide comprising introducing into a suitable host cell an expression construct encoding a cell-permeable polypeptide and an osteoinductive polypeptide positioned so that the osteoinductive polypeptide is expressed as part of a fusion protein with the cell-permeable polypeptide. The expression construct generally contains a promoter positioned to direct transcription of the polynucleotide sequence encoding the fusion product.
- The expression construct may further comprise a purification tag. The cell-permeable polypeptide may be chosen from the group consisting of HIV-TAT, VP-22, a growth factor signal peptide sequence, Pep-1, and a Drosophila Antp peptide. The osteoinductive polypeptide may be chosen from the group consisting of LMP-1, LMP-3,
SEQ ID NO 1,SEQ ID NO 2,SEQ ID NO 3,SEQ ID NO 4,SEQ ID NO 5,SEQ ID NO 6,SEQ ID NO 7,SEQ ID NO 8, BMP-2, BMP-4, BMP-6, BMP-7, TGF-beta 1 and Smad. - The invention provides osteoinductive polypeptides chosen from among the group consisting of
SEQ ID NO 1,SEQ ID NO 2,SEQ ID NO 3,SEQ ID NO 4,SEQ ID NO 5,SEQ ID NO 6,SEQ ID NO 7, andSEQ ID NO 8, or combinations thereof. - The invention also provides a method of inducing bone formation in a mammal comprising administering an effective amount of a fusion polypeptide comprising a protein transduction domain and at least one osteoinductive polypeptide. The fusion polypeptide may be administered as an implant and may be administered to at least one multipotent progenitor cell, which can be implanted into a mammal to promote osteoinduction.
- The invention also provides a polynucleotide encoding a fusion protein comprising a protein transduction domain and at least one osteoinductive polypeptide, the protein transduction domain being chosen from among a variety of protein transduction, membrane-translocation, and other similar polypeptides represented, for example, by HIV-TAT, VP-22, a growth factor signal peptide sequence, Pep-1, and a Drosophila Antp peptide. The osteoinductive polypeptide may be chosen from the group consisting of LMP-1, LMP-3,
SEQ ID NO 1,SEQ ID NO 2,SEQ ID NO 3,SEQ ID NO 4,SEQ ID NO 5,SEQ ID NO 6,SEQ ID NO 7,SEQ ID NO 8, BMP-2, BMP-4, BMP-6, BMP-7, TGF-beta 1 and Smad. - A method of inducing proteoglycan synthesis in a mammal is also provided. The method comprises administering an effective amount of a fusion polypeptide comprising a protein transduction domain and at least one osteoinductive polypeptide. The fusion polypeptide may be administered as an implant, and may be administered to at least one multipotent progenitor cell.
- An isolated fusion polypeptide comprising a membrane-translocating peptide operably linked to an osteoinductive polypeptide is provided by the invention. The membrane-translocating peptide may be chosen from the group consisting of HIV-TAT, VP-22, a growth factor signal peptide sequence, Pep-1, and a Drosophila Antp peptide and the osteoinductive polypeptide may be chosen from the group consisting of LMP-1, LMP-3,
SEQ ID NO 1,SEQ ID NO 2,SEQ ID NO 3,SEQ ID NO 4,SEQ ID NO 5,SEQ ID NO 6,SEQ ID NO 7,SEQ ID NO 8, BMP-2, BMP-4, BMP-6, BMP-7, TGF-beta 1 and Smad. - The invention provides a method of inducing osteoblast differentiation in a progenitor cell, the method comprising administering to the progenitor cell an effective amount of a fusion polypeptide comprising a protein transduction domain and at least one osteoinductive polypeptide. The protein transduction domain can be chosen from the group represented by HIV-TAT, VP-22, a growth factor signal peptide sequence, Pep-1, and Drosophila Antp polypeptides and the osteoinductive polypeptide may be chosen from the group represented by LMP-1, LMP-3,
SEQ ID NO 1,SEQ ID NO 2,SEQ ID NO 3,SEQ ID NO 4,SEQ ID NO 5,SEQ ID NO 6,SEQ ID NO 7,SEQ ID NO 8, BMP-2, BMP-4, BMP-6, BMP-7, TGF-beta 1 and Smad. -
FIG. 1 is a graph of BMP protein levels inmedia 6 days after treatment of annulus cells with LMP-1 (AdLMP-1 at MOI 25). The protein levels of BMP-2 and BMP-7 were increased significantly but BMP-4 and BMP-6 protein levels were not significantly different from media of untreated control cells. Each result is expressed as a ratio in proportion to the value from untreated cells. The mean and SEM for seven samples are reported. (* p<0.05 ** p<0.01 versus NT). -
FIG. 2 illustrates time-course BMP mRNA levels after treatment of annulus cells with LMP-1 (AdLMP-1 at MOI 25). BMP-2 mRNA level was upregulated significantly as early as 12 hours after AdLMP-1 treatement and reached aplateau 3 days after AdLMP-1 treatment. BMP-7 mRNA level was significantly increased 3 days after AdLMP-1 treatment. Each result is expressed as a ratio to values from untreated cells at the same time point. The mean and SEM for six samples are reported. (** p<0.01 versus NT for corresponding time point). -
FIG. 3 graphs aggrecan mRNA level in annulus cells after treatment with LMP-1 (AdLMP-1) measured by realtime PCR. The mRNA level of aggrecan was significantly increased 6 days after treatment with AdLMP-1 atMOI 25 as compared to untreated cells. The mRNA level of aggrecan was not changed in cells treated with AdLacZ as compared to untreated cells. Each result is expressed as a ratio to values from untreated cells. The mean and SEM for nine samples are reported. AdLMP-1:MOI 25, AdLacZ:MOI 25. (** p<0.01 versus NT). -
FIG. 4 is a table summarizing parameters and results of LMP-1 administration via a PTD/LMP-1 fusion protein in Harlan athymic rats. -
FIG. 5 is a table summarizing parameters and results of LMP-1 administration via a PTD/LMP-1 fusion protein in New Zealand White rabbits. -
FIG. 6 is a table summarizing results of administration of the indicated osteoinductive peptides via a PTD/peptide fusion protein in Harlan athymic rats, and, where indicated, New Zealand White rabbits. Bone growth was detected by x-ray, and, where indicated, was also palpable. - The inventors have discovered that a fusion protein comprising a protein transduction polypeptide and an osteoinductive polypeptide can be effectively used to promote bone development and intervertebral disc regeneration in vivo. The invention therefore provides osteoinductive polypeptides for intracellular delivery, polynucleotides encoding such osteoinductive polypeptides and protein transduction sequences, and methods of utilizing these fusion proteins to promote bone development and intervertebral disc regeneration in vivo.
- Previous work has demonstrated that LIM mineralization
protein splice variants 1 and 3 (LMP-1 and LMP-3) are osteoinductive, while LMP-2 does not appear to have such osteoinductive potential. A forty amino acid sequence corresponding to amino acids 94-133 of the amino acid sequence of human LMP-1 (hLMP-1) is common to both LMP-1 and LMP-3. The inventors therefore surmised that this unique region of the proteins might, in itself, have osteoinductive potential. Peptides comprising overlapping segments of this sequence were designed and used to test the inventors' hypothesis. Their results indicate that peptides derived from LMP-1 and LMP-3 have osteoinductive potential. When used in vivo, these peptides demonstrated the ability to induce bone formation.FIG. 6 indicates peptides which have demonstrated osteoinductive functionality when introduced into cells as part of the fusion protein of the present invention in the method of the present invention. - Protein transduction polypeptides facilitate the uptake and subsequent expression of nucleic acid sequences or therapeutic proteins. In the literature, they may be referred to alternately, and often interchangeably, as cell-permeable peptides, protein transduction domains, membrane transport sequences, and membrane-translocating peptides. They function to transport an attached peptide, polypeptide, or protein through the cell membrane into the interior of the cell in a receptor-independent manner. A fusion protein utilizing a protein transduction domain can comprise one or more peptides, polypeptides, or proteins operably linked to the protein transduction domain. In the present invention, such a fusion protein can comprise a protein transduction domain and at least one osteoinductive peptide, polypeptide, or protein, or combinations thereof. These peptides can be used to transduce autologous, allogeneic, or xenogeneic cells or tissues of ectodermal, mesenchymal, or hematopoetic origin and infuse or implant them into the recipient to induce or contribute to the formation of new tissue. In the method of the present invention, such polypeptides facilitate the uptake of proteins that can induce cells such as, for example, multipotent progenitor (stem) cells, to produce, for example, BMP-2, BMP-4, BMP-6, BMP-7, BMP-9, BMP-12, BMP-13, aggrecan, collagen type I, collagen type II, versican, lumican, fibromodulin, biglycan, and decorin. Effective amounts of polypeptides of the present invention are indicated in the experimental design and results disclosed herein, but may also be determined by one of skill in the art based upon the disclosure of effective amounts provided herein.
- Human LIM mineralization protein-1 (hLMP-1), one of a family of LMP proteins, is an intracellular regulatory protein that can enhance the efficacy of bone mineralization in vitro and in vivo. Human LMP-1 is so named because it possesses a characteristic structural motif composed of two special zinc fingers that are joined by an amino acid spacer. LIM mineralization protein splice variants and their uses have been described by the inventors in U.S. Pat. Nos. 6,300,127; 6,444,803; and 6,521,750. The sequences of LMP-1, LMP-2, and LMP-3 have also been disclosed in those patents. On Jul. 22, 1997, a sample of 10-4/RLMP (Rattus norvegicus LIM mineralization protein cDNA) in a vector designated PCMV2/RLMP (which is vector pRc/CMV2 with insert 10-4 clone/RLMP) was deposited with the American Type Culture Collection (ATCC), 12301 Parklawn Drive, Rockville, Md. 20852, and was assigned accession number 209153. On Mar. 19, 1998, a sample of the vector pHis-A with insert HLPM-is (Homo sapiens LIM mineralization protein cDNA) was deposited at the American Type Culture Collection and assigned accession number 209698.
- A
serotype 5 adenovirus (Ad5) has been employed for the delivery of LMPs to a variety of cells and tissues including cells derived from peripheral blood and bone marrow. (Boden, et al., “Adenoviral Delivery of LMP-1 Induces Consistent Spine Fusion”, 47th Annual Meeting, Orthopaedic Research Society, San Francisco, Calif. (2001)). However, the Ad5 virus utilizes a specific receptor (i.e., coxsackie adenovirus receptor or CAR), which is absent, or present in limited quantities, in these cells. Protein transduction across the cell membrane to facilitate intracellular delivery of proteins without receptor-mediated mechanisms offers an attractive alternative to allow treatment of a variety of cell and tissue types. - The actions of LMPs and other osteoinductive proteins indicate that they have therapeutic potential in a variety of tissues, such as brain, spinal cord, peripheral nerve, bone, cartilage, intervertebral discs, connective tissue, tendons, and ligaments. Delivery of LMPs, for example, to a variety of tissues can be accomplished by delivery systems comprising, for example, collagen, collagen ceramic combinations, demineralized bone matrix, natural or synthetic polymers such as elastin, fibrin, polylactic acid, polyglycolic acid, polycaprolactone, polypropylene fumarate, polyvinyl alcohol, polyesters, polyethers, polyhydroxyls, and structural implants. Such matrices may be injectable, moldable, solid implants, structural implants, or combinations thereof.
- The present inventors have discovered that PTDs can be used to deliver functional osteoinductive proteins into cells and to effectively induce osteogenesis and proteoglycan synthesis. Such cell-permeable peptide import (CPPI) provides a method for delivering osteoinductive proteins into a variety of cell types. An 11 amino acid peptide, initially derived from the HIV-1 TAT protein, was successfully used to deliver osteoinductive proteins into cells. The TAT peptide can be over-expressed in bacterial cells using the pTAT-HA vector. A recombinant human gene can be inserted into this vector in such a manner as to produce a fusion protein containing both the TAT peptide sequence as well as the gene product of interest. Furthermore, the PTD/osteoinductive polypeptide can be expressed in conjunction with a polyHis tag in order to facilitate isolation and purification of the fusion protein. The pTAT-HA vector and a purification protocol for TAT fusion proteins have been described previously by Nagahara, et al. (Nature Medicine. Vol. 4) p. 1449-1452, December 1998).
- A peptide sequence as found in a variety of PTDs can facilitate entry into cells in a coxsackie-adenovirus receptor (CAR)-independent manner, thereby improving transduction efficiencies to target cells and subsequently lowering the required amounts of nucleic acid or protein needed to achieve the desired effect. PTD fusion proteins therefore provide a therapeutic tool that may be used to reduce the cost of therapy.
- In one embodiment of the invention, a fusion protein of a protein transduction domain and an osteoinductive protein is provided. Osteoinductive proteins include, but are not limited to, LIM mineralization proteins (LMPs), bone morphogenetic proteins (BMP) and Smad proteins. As used herein, “osteoinductive proteins,” “osteoinductive polypeptides,” and “osteoinductive peptides” may be used interchangeably to refer to either a peptide or polypeptide of varying length or a full-length protein with osteoinductive functionality.
- A fusion protein comprising a PTD and a LIM mineralization protein is provided as one embodiment of the invention. The fusion protein can comprise a PTD and one or more LIM mineralization proteins or polypeptides. Useful LIM mineralization proteins include, for example, LMPs as disclosed in U.S. Pat. Nos. 6,300,127; 6,444,803; and 6,521,750; as well as pending U.S. patent application Ser. No. 09/959,578, filed Apr. 28, 2000. Preferably, the LMP is RLMP, HLMP-1, HLMP-1s, HLMP-2, HLMP-3, or a peptide derived therefrom. These peptides can include, for example,
SEQ ID NO 1,SEQ ID NO 2,SEQ ID NO 3,SEQ ID NO 4,SEQ ID NO 5,SEQ ID NO 6,SEQ ID NO 7, or a polypeptide as inSEQ ID NO 8. - The nucleotide sequence encoding the LIM mineralization protein preferably hybridizes under standard conditions to a nucleic acid molecule complementary to the full length of the following sequence:
-
- tcctcatccg ggtcttgcat gaactcggtg or hybridizes under highly stringent conditions to a nucleic acid molecule complementary to the full length of the following sequence:
- gcccccgccc gctgacagcg ccccgcaa, or both.
- “Standard hybridization conditions” will vary with the size of the probe, the background and the concentration of the nucleic acid reagents, as well as the type of hybridization (in situ, Southern blot, or hybrization of DNA-RNA hybrids (Northern blot)). The determination of “standard hybridization conditions” is within the level of skill in the art. Methods include, for example, those described in U.S. Pat. No. 5,580,775 (Fremeau, et al.), Southern, J. Mol. Biol., 98:503 (1975), Alwine, et al., Meth. Enzymol., 68:220 (1979), and Sambrook, et al., Molecular Cloning: A Laboratory Manual, 2nd edition, Cold Spring Harbor Press, 7.19-7.50 (1989).
- One set of standard hybrization conditions involves pre-hybridizing a blot at 42° C. for 2 hours in 50% formamide, 5×SSPE (150 nM NaCl, 10 mM Na H2PO4 [pH 7.4], 1 mM EDTA [pH 8.0])15× Denhardt's solution (20 mg Ficoll, 20 mg polyvinylpyrrolidone and 20 mg BSA per 100 ml water), 10% dextran sulphate, 1% SDS and 100 μg/ml salmon sperm DNA. A 32P labeled cDNA probe is added, and further hybridizing continued for 14 hours. Afterward, the blot is washed twice with 2×SSPE, 0.1% SDS for 20 minutes at 22° C., followed by a 1 hour wash at 65° C. in 0.1×SSPE, 0.1% SDS. The blot is then dried and exposed to x-ray film for 5 days in the presence of an intensifying screen.
- Under “highly stringent conditions”, a probe will hybridize to its target sequence if those two sequences are substantially identical. Techniques are known to those of skill in the art for determining the conditions under which only substantially identical sequences will hybridize while non-identical sequences will not.
- As used herein, the term “protein” is intended to include mimetics and the term “amino acid” is intended to include L-form, D-form, and modified amino acids. These substitutions may be made by one of skill in the art, using the known structural similarities between the molecules. The amino acid sequence is also intended to include any peptide or protein sequence that may include additional amino acids either N-terminal or C-terminal to the listed sequence, or both. The term “osteoinductive protein” is intended to include variants or biologically active fragments of the polypeptide, as well as full-length proteins.
- It is well known in the art that a single amino acid may be encoded by more than one nucleotide codon, and that the nucleotide sequence may be modified to produce an alternate nucleotide sequence that encodes the same peptide. Therefore, alternate embodiments of the present invention include alternate DNA sequences encoding peptides containing the amino acid sequences as previously described. DNA sequences encoding peptides containing the claimed amino acid sequence include DNA sequences which encode any combination of the claimed sequence and other amino acids located N-terminal or C-terminal to the claimed amino acid sequence. It is to be understood that amino acid and nucleic acid sequences may include additional residues, particularly N- or C-terminal amino acids or 5′ or 3′ nucleotide sequences, and still be essentially as set forth in the sequences disclosed herein, as long as the sequence confers osteoinductive potential upon the expressed polypeptide or protein.
- Additional nucleic acid bases may be added either 5′ or 3′ to the nucleotide sequence encoding the osteoinductive polypeptide, and may be combined with other DNA sequences, such as promoters, polyadenylation signals, additional restriction enzyme sites, multiple cloning sites, other coding segments, and the like. Therefore, overall length of such a polynucleotide may vary considerably.
- It is to be understood that a “variant” of a polypeptide is not completely identical to the native protein. A variant of an osteoinductive polypeptide or protein, for example, can be obtained by altering the amino acid sequence by insertion, deletion or substitution of one or more amino acids. The amino acid sequence of the polypeptide or protein can be modified, for example, by substitution to create a polypeptide having substantially the same or improved qualities as compared to the native polypeptide. The substitution may be a conserved substitution. A “conserved substitution” is a substitution of an amino acid with another amino acid having a side chain that is similar in polar/nonpolar nature, charge, or size. The 20 essential amino acids can be grouped as those having nonpolar side chains (alanine, valine, leucine, isoleucine, proline, phenylalanine, and tryptophan), uncharged polar side chains (methionine, glycine, serine, threonine, cystine, tyrosine, asparagine and glutamine), acidic side chains (aspartate and glutamate), and basic side chains (lysine, arginine, and histidine). Conserved substitutions might include, for example, Asp to Glu, Asn, or Gln; His to Lys, Arg or Phe; Asn to Gln, Asp or Glu; and Ser to Cys, Thr or Gly. Alanine, for example, is often used to make conserved substitutions.
- To those of skill in the art, variant polypeptides can be obtained by substituting a first amino acid for a second amino acid at one or more positions in the polypeptide structure in order to affect biological activity. Amino acid substitutions may, for example, induce conformational changes in a polypeptide that result in increased biological activity.
- Those of skill in the art may also make substitutions in the amino acid sequence based on the hydrophilicity index or hydropathic index of the amino acids. A variant amino acid molecule of the present invention, therefore, has less than one hundred percent, but at least about fifty percent, and preferably at least about eighty to about ninety percent amino acid sequence homology or identity to the amino acid sequence of a polypeptide comprising the amino acid sequence of LMP-1, LMP-2, LMP-3,
SEQ ID NO 1,SEQ ID NO 2,SEQ ID NO 3,SEQ ID NO 4,SEQ ID NO 5,SEQ ID NO 6,SEQ ID NO 7, or a polypeptide as inSEQ ID NO 8. Therefore, the amino acid sequence of the variant osteoinductive polypeptide or protein corresponds essentially to the native osteoinductive polypeptide or protein amino acid sequence. As used herein, “corresponds essentially to” refers to a polypeptide sequence that will elicit a similar biological and enzymatic activity to that generated by an osteoinductive polypeptide or protein comprising LMP-1, LMP-2, LMP-3,SEQ ID NO 1,SEQ ID NO 2,SEQ ID NO 3,SEQ ID NO 4,SEQ ID NO 5,SEQ ID NO 6,SEQ ID NO 7, or a polypeptide as in SEQ ID NO 8., such activity being at least about 70 percent that of the native osteoinductive protein, and more preferably greater than 100 percent of the activity of the native osteoinductive protein. - A variant of the osteoinductive protein may include amino acid residues not present in a corresponding osteoinductive protein comprising LMP-1, LMP-2, LMP-3,
SEQ ID NO 1,SEQ ID NO 2,SEQ ID NO 3,SEQ ID NO 4,SEQ ID NO 5,SEQ ID NO 6,SEQ ID NO 7, orSEQ ID NO 8, or may include deletions relative to the osteoinductive protein comprising LMP-1, LMP-2, LMP-3,SEQ ID NO 1,SEQ ID NO 2,SEQ ID NO 3,SEQ ID NO 4,SEQ ID NO 5,SEQ ID NO 6,SEQ ID NO 7, orSEQ ID NO 8. A variant may also be a truncated “fragment,” as compared to the corresponding protein comprising LMP-1, LMP-2, LMP-3,SEQ ID NO 1,SEQ ID NO 2,SEQ ID NO 3,SEQ ID NO 4,SEQ ID NO 5,SEQ ID NO 6,SEQ ID NO 7, or SEQ ID NO 8., the fragment being only a portion of the full-length protein or polypeptide. - Bone morphogenetic proteins (BMPs) are members of the TGF-β superfamily of proteins. BMPs have been shown to induce ectopic bone or cartilage formation. According to the invention, a fusion protein of a PTD and a bone morphogenetic protein is also provided. BMPs include, for example, BMP-2, BMP-3, BMP-3b, BMP-4, BMP-5, BMP-6, BMP-7, BMP-8, BMP-9, BMP-10, BMP-11, BMP-12, BMP-13, BMP-14, BMP-15, GDF-1, GDF-3, GDF-8 and GDF-9. Bone morphogenetic proteins BMP-2, BMP-4, BMP-5, BMP-6, BMP-7, BMP-8, or BMP-9 can be especially useful in the method of the present invention.
- Smad proteins are intracellular proteins that mediate signaling from receptors for extracellular TGF-beta-related factors (Heldin. et al., “TGF-β Signalling from Cell Membrane to Nucleus through SMAD Proteins”, Nature, Vol. 390 (1997)). Smad proteins can be activated (i.e., phosphorylated) by the binding of a BMP to its receptor. Upon activation, the Smad proteins translocate to the nucleus where they regulate gene expression. A fusion protein of a PTD and a Smad protein is also provided in the present invention. Smad-1, Smad-2, Smad-3, Smad-4, Smad-5, Smad-6, Smad-7 or Smad-8 can be especially useful for promoting osteoinduction when delivered as a fusion protein with a protein transduction domain as in the present invention.
- The protein transduction domain according to the invention can be any peptide, mimetic, or peptide nucleic acid (PNA) sequence that can traverse the plasma membrane of a cell to deliver an attached or accompanying protein, peptide, or nucleic acid to the interior of the cell. The inventors have demonstrated that osteoinductive proteins can be delivered intracellularly (as a fusion protein moiety, for example) without impairing their ability to promote osteoinduction and proteoglycan synthesis. PTDs include, for example, polypeptides derived from the Drosophila homeotic transcription factor Antennapedia (Antp), the herpes simplex virus (HSV) protein VP22, signal peptide sequences from growth factors such as Kaposi's fibroblast growth factor (K-FGF) (Lin, et al., J. Biol. Chem., Vol. 270, p. 14255-14258, 1995) a membrane translocation sequence derived from the K-FGF signal peptide sequence (Rojas, et al, Nat. Biotech., Vol. 16, p. 370-375, 1998), and the human immunodeficiency virus (HIV)-1 transcriptional activator TAT (Fawell, et al., Proc. Natl. Acad. Sci. USA, Vol. 91, p. 664-668,1994). PTDs are disclosed in U.S. Pat. No. 5,652,122, and in Schwarze. et al., “Protein Transduction: Unrestricted Delivery into all Cells”, Trends in Cell Biology, Vol. 10 (2000). The inventors have found the HIV-TAT PTD to be especially useful in the present invention.
- A nucleic acid comprising a nucleotide sequence encoding a fusion protein operably linked to a promoter, wherein the fusion protein comprises a protein transduction domain (PTD) and an osteoinductive protein, is also provided. The nucleic acid can be part of a vector (e.g., an expression vector such as a plasmid). Osteoinductive proteins can include, for example, LIM mineralization proteins, bone morphogenetic proteins, Smad proteins, and osteoinductive peptides and polypeptides derived therefrom. Examples of osteoinductive peptides and polypeptides include
SEQ ID NO 1,SEQ ID NO 2,SEQ ID NO 3,SEQ ID NO 4,SEQ ID NO 5,SEQ ID NO 6,SEQ ID NO 7, andSEQ ID NO 8. - Methods of delivering osteoinductive proteins into cells are also provided by the present invention. In a method of the invention, at least one osteoinductive protein can be delivered into a cell via transduction wherein a fusion protein comprising a protein transduction domain (PTD) and an osteoinductive protein is contacted with the cell so that the fusion protein is delivered into the cell, the delivery being facilitated by the protein transduction domain or cell-permeable peptide
- The cells into which the osteoinductive proteins can be delivered include, for example, osseous (i.e., bone forming) and non-osseous cells. Such cells may include, for example, buffy coat cells, stem cells (e.g., mesenchymal stem cells, multipotent and pluripotent stem cells), intervertebral disc cells (e.g., cells of the annulus fibrosus and cells of the nucleus pulposus), mesenchymal cells, hematopoietic cells, endothelial cells and muscle cells. Stem cells can be derived from autalogous or allogeneic tissue.
- Cells transduced with or expressing a fusion protein of a protein transduction domain (PTD) and an osteoinductive protein are also provided. Such cells may include, but are not limited to, buffy coat cells, stem cells (e.g., mesenchymal stem cells and pluripotential stem cells), intervertebral disc cells (e.g., cells of the annulus fibrosus and cells of the nucleus pulposus), mesenchymal cells, hematopoietic cells, endothelial cells and muscle cells. Cells containing a fusion protein of a PTD and an osteoinductive protein as described herein can be implanted into the body of a mammal to induce bone formation. Methods of inducing bone formation using LMPs as osteoinductive proteins are described, for example, in U.S. Pat. No. 6,300,127. Cells comprising a fusion protein of a PTD and an osteoinductive protein may also be implanted into the intervertebral disc, for example, to stimulate proteoglycan and/or collagen synthesis as set forth in U.S. patent application Ser. No. 10/292,951, filed Nov. 13, 2002, pending.
- A Conjugate of a PTD and a nucleic acid comprising a nucleotide sequence encoding an osteoinductive protein is also provided. The PTD/nucleic acid conjugate can be used to direct over-expression of an osteoinductive protein to promote bone formation or disc regeneration, for example. Osteoinductive proteins encoded by the nucleotide sequence can include, but are not limited to, LMPs, BMPs, and Smad proteins. Methods for chemically linking peptides to nucleic acids are known in the art. One such method is described in U.S. Pat. No. 5,652,122. The nucleic acid can be in the form of an expression vector comprising a nucleotide sequence encoding an osteoinductive protein operably linked to a promoter.
- Methods of the present invention can be used to induce the expression of one or more bone morphogenetic proteins or transforming growth factor-β proteins in a cell as described in copending U.S. patent application Ser. No. 10/382,844, filed Mar. 7, 2003. For example, the expression of one or more proteins selected from the group consisting of BMP-2, BMP-4, BMP-6, BMP-7, TGF-β1 and combinations thereof can be induced by contacting a cell with a fusion protein comprising a PTD and an osteoinductive protein according to the invention. Additionally, cells which over-express one or more proteins selected from the group consisting of BMP-2, BMP4, BMP-6, BMP-7, TGF-β1 and combinations thereof are also provided according to the invention. The cell can be any somatic cell including, but not limited to, a stem cell, a buffy coat cell, a bone marrow cell, a peripheral blood cell or a fat cell. The cell can be a stem cell derived from autologous or allogeneic tissue.
- Stem cells, or multipotent progenitor cells, can provide a source of cells from which to generate osteoblasts. These cells may be isolated at various stages of differentiation and induced to differentiate in specific lineage pathways. The cells may be used to treat bone diseases such as osteoporosis or osteogenesis imperfecta, as well as non-healing fractures. Core binding factor alpha 1 (Cbfa1) has been demonstrated to be necessary for osteogenesis. BMP-2, BMP-4, and BMP-7, which are known to induce osteoblast differentiation, up-regulate Cbfa1 expression. BMP-8 and Smad-3 are up-regulated during osteoblast differentiation. Activation of TGF-beta/BMP-Smad signaling has been shown to promote Cbfa1 expression, and osteoblast differentiation. The present invention provides fusion proteins comprising functional BMPs, LMPs, Smad proteins, or a combination thereof, for example, to promote osteoblast differentiation in cells such as human bone marrow-derived mesodermal progenitor cells. Suitable cells may include, for example, multipotent cells such as those described by Jiang, et al. (Nature, Vol. 418, p. 41-49, 2002). Administration of suitable osteoinductive proteins or polypeptides, or combinations thereof, can be performed ex vivo before implantation of the cells, or in vivo following implantation or injection. For in vivo administration, osteoinductive proteins of the present invention can be injected at a target site so that they can be delivered to the interior of nearby cells via a PTD or cell-permeable peptide, for example. Alternately, an implant comprising a carrier in combination with a PTD/osteoinductive polypeptide may be used. Implants may contain reservoirs in which to place the PTD/osteoinductive polypeptide for release into the surrounding tissue, or may comprise a porous composition that has been soaked in a solution containing one or more PTD/osteoinductive polypeptide constructs. Hydrogels, time-release capsules or spheres, liposomes, microspheres, nanospheres, biodegradable polymers, or other such drug delivery systems may also be employed to deliver peptides and proteins of the present invention to target cells and tissues. U.S. Pat. No. 6,475,516 (DiCosmo, et al.), for example, provides hydrogels loaded with liposomal therapeutic agents such as antibiotics, the hydrogels being covalently bonded to the surface of an in-dwelling medical device such as an implant.
- A hallmark of disc degeneration is the decreased production of proteoglycans in the disc, especially sulfated-glycosaminoglycans (sGAG) and aggrecan. A decrease in the production rate of aggrecan, the major proteoglycan of the intervertebral disc, is an important factor in intervertebral disc degeneration. Because of the central role of proteoglycans in the function of the intervertebral disc, restoration of normal proteoglycan production of the intervertebral disc may be critically important in any biological treatment of intervertebral disc degeneration.
- The inventors performed experiments which demonstrated that LMP-1 over-expression or intracellular administration increases disc cell proteoglycan production in vitro and-in vivo. LMP-1 over-expression induces the upregulation of BMP-2 and BMP-7 mRNA in vitro and in vivo. Noggin, which specifically inhibits these BMP-2 and BMP-7, inhibits proteoglycan upregulation by AdLMP-1, indicating that LMP-1 induced upregulation of proteoglycan is mediated by the upregulation of BMPs. LMP-1 administration via gene therapy or protein therapy (e.g., delivery by PTD conjugates) therefore can be used to stimulate proteoglycan production in discs and play a therapeutic role in disc regeneration.
- Cytokines such as TGF-β1, IGF-1, and EGF have been shown to stimulate intervertebral disc cell mitosis and, to some extent, proteoglycan production. Other cytokines such as BMP-2 and BMP-7 have also been shown to be effective in stimulating proteoglycan production. Because cytokines are small water soluble molecules, however, they rapidly diffuse away from the intervertebral disc or become inactivated by other regulatory factors. LIM Mineralization Protein-1 (LMP-1) is an intracellular regulatory molecule that is known to induce the secretion of multiple different BMPs from leukocytes and osteoblasts. By delivering LMP-1, LMP-2, LMP-3, or an osteoinductive peptide derived from LMP-1 or LMP-3, or a combination thereof, into the cell, particularly via a PTD/nucleic acid conjugate, BMP production can be stimulated from within the cells. Suitable osteoinductive peptides include, for example,
SEQ ID NO 1,SEQ ID NO 2,SEQ ID NO 3,SEQ ID NO 4,SEQ ID NO 5,SEQ ID NO 6,SEQ ID NO 7, or a polypeptide as inSEQ ID NO 8. - The present invention may be more fully understood by reference to the following non-limiting examples.
- The synthesis and use of a (His)6 TAT-LMP protein conjugate, comprising the protein transduction domain of HIV-Tat and the LMP-1 protein, is described below. The pTAT-HA-vector was obtained under a material transfer agreement from Washington University (St. Louis, Mo.).
- An NcoI restriction site was added to the 5′ end of hLMP-1 by utilizing pcDNA3.1/hLMP-1 as the template for PCR with the following primers:
Fwd: 5′-CCATGGAflCCflCAAAGTAGTGC-3′ Rev: 5′-CAGGGCGGGCGGCTGGTAG-3′
The reaction was performed at: 95° C. for 2 Min.[95° C., 30 sec; 66° C., 30 sec; 72° C., 1 mm]×25, and 72° C. 10 mm. The PCR product was cloned into PCRII-TOPO vector (Invitrogen) and appropriate clones were identified by sequencing. - Construction of the (His)6 TAT-LMP vector was accomplished by restriction endonuclease digestion of plasmid clones with NcoI and ClaI, and purification of the resulting product by agarose gel electrophoresis and electroelution. The full-length hLMP-1 sequence was isolated by restriction digest of the pcDNA3.1/hLMP-1 vector with ClaI and EcoRI, and purification of the resulting product by agarose gel electrophoresis and electroelution. The pTAT-HA-vector was also subjected to restriction digestion with NcoI and EcoRI, and the resulting linearized vector was purified by agarose gel electrophoresis and electroelution. Products were then ligated by standard procedures overnight at 16° C. Correctly ligated products (5′ hLMP-1+3′ hLMP-1+linearized pTAT-HA-vector=(His)6 TAT-LMP vector) were determined by subsequent agarose gel electrophoreses and molecular weight determinations.
- Ligation products were transfected into BL21 (DE3) competent cells and suitable clones were identified by restriction analysis.
- Synthesizing and Harvesting the (His)6 TAT-LMP Protein
- Appropriate BL21 (DE3) Eschericia coli-colonies containing positive clones of (His)6 TAT-LMP fusion constructs were grown to 0.8 OD (600 nm) and protein production was induced with 100 μM IPTG for 4 h at 37° C. Induced cells were harvested by standard methods and lysed (20 mM PO4 buffer, pH 7.2, 8 M urea, 100 mM NaCl, 20 mM Imidazole) by sonication (4×20 S, each with 2 mm rest periods, 4° C.).
- The lysate was clarified by centrifugation (10000×g) and the resulting supernatant applied to a Ni2+ sepharose affinity column (Invitrogen) under gravity flow conditions. The column was washed (20 mM PO4 buffer, pH 6.0, 8 M Urea, 250 mM NaCl, 20 mM Imidazole) and then bound proteins eluted (20 mM PO4 buffer, pH 4.0, 8 M Urea, 500 mM NaCl).
- Eluate was subjected to anion exchange chromatography (Hitrap Q HP, 5 mL, Pharmacia) using a linear gradient (Buffer A: 20 mM sodium carbonate,
pH 11, 8 M Urea; Buffer B: 20 mM sodium carbonate,pH 11, 8 M Urea, 2 M NaCl) from 0% Buffer B to 100% Buffer B (40 mm @ 5 mL/min). Eluted fractions (5 mL) were analyzed for the presence of hLMP-1 by SDS-PAGE and Western blot analyses. - Fractions positive for hLMP-1 were subjected to hydrophobic interaction chromatography (Hitrap® Phenyl-sepharose, 5 mL, Pharmacia). Elution (Buffer A: 20 mM sodium carbonate, pH 10.5, 1.5 M ammonium sulfate; Buffer B: 20 mM sodium carbonate, pH 10.5) was performed with a linear gradient of 0% to 100% Buffer B for 20 mm @ 5 mL/mm. Eluted fractions (5 mL) were analyzed for the presence of hLMP-1 by SDS-PAGE and Western blot analyses. Fractions positive for (His)6 TAT-LMP fusion protein were lyophilized until used.
- Use of (His)6 TAT-LMP Fusion Protein for de novo Bone Formation
- Lyophilized fractions (55 pg) were resuspended into 40 mM KOH to (Stock Solution; 1.0 μM). Human buffy coat cells were prepared as described in Viggeswarapu, et al., J. Bone Joint Surg., Vol. 83(3), p. 364 (2001). These cells were mixed with 5 μL of (His)6 TAT-LMP fusion protein in alpha MEM (Gibco) and incubated for 30 min.@ 37° C.
- An appropriate volume of human buffy coat cells containing the (His)6 TAT-LMP fusion protein was then applied to a porous collagen matrix for implantation. To demonstrate de novo bone formation in vivo, 100 μL of cell suspension was applied via sterile pipette to a sterile 5×5 mm type I human collagen disc for implantation into rats. A similar quantity of cell suspension was applied to 10×25 mm sheets for implantation to promote spine fusion. Discs were surgically implanted subcutaneously in the chest/abdomen of 4-5 week old athymic rats (rnu−/rnu−). The animals were sacrificed at 4 weeks, at which time discs were excised, fixed in 70% ethanol, and analyzed by radiography and undecalcified histologic examination (sectioned to 5 μm and stained with Goldner Trichrome).
- In rabbits, posterolateral lumbar spine arthrodesis was performed and carrier matrix was implanted (i.e., collagen sponge with 15% hydroxyapatite/85% tricalcium phosphate) with each side of the spine receiving 4×106 transduced buffy coat cells. After 4 weeks, rabbits were euthanized and their lumbar spines excised. The status of the spine fusion was assessed by blinded manual palpation of the motion segments to detect residual motion (indicative of failed fusion), radiographs, CT scans, and non-decalcified histology.
- In both rats and rabbits, radiography revealed a high level of mineralized bone formation conforming to the form of the original collagen discs or sheets containing LMP-1 transfected human buffy coat cells. No mineralized bone formation was observed in the control, and the original collagen discs or sheets appeared to be undergoing absorption. Histology revealed new bone trabeculae lined with osteoblasts in the LMP-1 transduced implants, whereas no bone was seen, and the carrier was partially resorbed, in the controls.
- Use of Osteoinductive Peptides to Induce In Vivo Bone Formation
- Protocols were essentially as described above. Peptides were applied to 4 separate implants (3 for rabbit), 250 microliters per disc, 6M/ml. Implants comprised collagen discs. Implants were placed within the chest of Harlan athymic rats or New Zealand White rabbits. Dose ranges tested were 5 nM, 10 nM, 12.5 nM, 15 nM, 17.5 nM, 20 nM, 22.5 nM, and 25 nM. Results are shown in
FIG. 6 . - LMP-1 Stimulation of sGAG Synthesis
- In vitro experiments with lumbar intervertebral disc cells from Sprague-Dawley rats were performed by treating the cells with an adenovirus containing an LMP-1 nucleotide sequence insert (AdLMP-1) at various doses (multiplicity of
infection - In vivo gene therapy experiments were performed in New Zealand White rabbits. Lumbar discs were injected with either AdLMP-1 (experimental) or an adenovirus carrying a marker gene (AdLacZ—control) at three different doses (106, 107, and 108 pfu/disc). Three weeks later the injected discs were harvested and the mRNA level of total LMP-1 (endogenous), over-expressed LMP-1, aggrecan, BMP-2, and BMP-7 were measured.
- AdLMP-1 at a multiplicity of infection (MOI) of 25 was sufficient to induce the maximal level of sGAG upregulation. A period of 6 days in monolayer culture was required to reach the maximal level of sGAG upregulation after AdLMP-1 treatment (MOI 25). Aggrecan mRNA increased by 2 times compared to control. When the cells were cultured in alginate, the effect of AdLMP-1 treatment on sGAG production was sustained for 3 weeks. Six days after AdLMP-1 treatment, BMP-2 and BMP-7 mRNA levels increased significantly to 3.0+0.2 and 2.8+0.3 times that of controls (p<0.01), respectively. BMP-4 and BMP-6 mRNA levels were unchanged. BMP-2 and BMP-7 protein levels in the media were increased significantly (p<0.01) compared to control. In contrast, BMP-4 and BMP-6 protein levels were not elevated. Noggin at 3200 ng/ml completely blocked the upregulation of proteoglycan by AdLMP-1. Endogenous levels of LMP-1 mRNA were detected in lumbar nucleus pulposus. In vivo discs injected with 107 pfu/disc of AdLMP-1 had a significantly elevated level of LMP-1, BMP-2, and BMP-7 mRNA levels compared to control.
- In vitro experiments were carried out with Sprague-Dawley (SD) rat lumbar disc cells. Two tailed student t-tests were used to compare the experimental group to control group. The error bars in the figures present 1 SEM.
- A replication
deficient type 5 adenovirus carrying the cDNA for the human LMP-1 gene was used (AdLMP-1). Monolayer culture experiments with SD annulus cells were (carried out to determine the relationship between virus dose and over-expressed LMP-1 mRNA expression using realtime PCR method using a primer that is specific for only the virally delivered LMP-1 cDNA. Monolayer culture experiments with SD annulus cells were performed to determine the relationship between virus dose and sGAG production. The sGAG levels were measured with a DMMB method. The optimal dose of AdLMP-1 was defined as the lowest dose which led to the plateau level of sGAG production. Using the optimal dose (25 MOI), a time-course experiment (9 days) was carried out to determine the minimal length of time (6 days) necessary to reach the plateau level of sGAG production The aggrecan mRNA level of AdLMP-1 treated annulus cells were compared to controls using the optimal viral dose and time determined above (AdLMP-1 at 25 MOI and six days after treatment). In order to ascertain that nucleus cells responded in a similar fashion to annulus cells, the effect of AdLMP-1 on sGAG production and cell number was determined for both annulus and nucleus cells at 25 MOI six days after treatment. To investigate the more long-term effects of AdLMP-1 treatment, sGAG accumulation in the alginate of SD annulus cells cultured in alginate was determined at 1, 2, and 3 weeks. All experiments were repeated at least twice. - Monolayer culture experiments with SD annulus cells were performed using AdLMP-1 at
MOI 25. Briefly, the mRNA levels of LMP-1, BMP-2, BMP-4, BMP-6, and BMP-7 were measured with real-time PCR analysis at 0.5, 1, 3, and 6 days after AdLMP-1 treatment. Levels of BMP-2, BMP-4, BMP-6, and BMP-7 were measured in the media six days after treatment using a direct ELISA method. To determine the effect of blocking BMP activity, noggin was added to the culture media at the start of AdLMP-1 treatment. The change in sGAG level with or without noggin at various concentrations after treatment with AdLMP-1 was determined in a six day experiment - To determine the in vivo effects of administration of LMP-1 (via. AdLMP-1) on aggrecan, BMP-2, and BMP-7, four New Zealand White (NZW) rabbits (3-4 kg) were used. The anterior lumbar discs L2/3, L3/4, L4/5, and L5/6 were exposed through a left retroperitoneal approach. Either the experimental virus (AdLMP-1) or control virus (AdGFP—
type 5 adenovirus with Green Fluorescence Protein cDNA as insert) at 107 plaque-forming units (pfu) was injected into each of the exposed disc nucleus in alternating fashion (i.e., two discs injected with AdLMP-1 and two discs injected with AdGFP in each rabbit). The virus was administered by delivery in 10 microliters of phosphate buffered saline through a 30G Hamilton syringe. After 3 weeks, nucleus pulposus tissue from the injected lumbar discs was harvested. Nucleus tissues from two rabbits were pooled into either control or experimental disc groups to obtain sufficient mRNA for further analysis. Reverse transcription and real-time PCR were used to quantitate the mRNA levels of total LMP-1, BMP-7, and aggrecan. The primers for total LMP-1 were designed to identify both endogenous and over-expressed LMP-1. - In a second in vivo demonstration, various doses of the AdLMP-1 virus were used to establish a dose response relationship. AdLMP-1 at three different doses (106, 107, 108 pfu) and AdGFP at a single dose (107 pfu) were administered. In this experiment, all the discs from each animal were injected with a single dose of virus instead of alternating virus type as in the previous experiment. Eight NZW rabbits (3-4 kg) were used, two rabbits for each of the four virus groups. The rabbits were euthanized three weeks later and the nucleus pulposus was harvested. The harvested tissue from within each treatment group was pooled, mRNA isolated and used to generate corresponding cDNA. Real-time PCR was used to quantitate the mRNA levels of total LMP-1, over-expressed LMP-1, BMP-2, BMP-7, and aggrecan.
- The relative amounts of over-expressed LMP-1 mRNA at 12 hours after virus treatment at different doses (
MOI MOI 5. No detectable levels of over-expressed LMP-1 mRNA could be found in the untreated control or the AdLacZ control groups, indicating that AdLMP-1 induced over-expression of LMP-1 in annulus cells in a dose dependent manner. - The sGAG concentration in the culture media from annulus cells was determined 6 days after treatment with AdLMP-1 at different doses. The sGAG concentration in the culture media on
day 6 is a measure of the total sGAG produced by the cells over the three-day time period between media change and the sGAG measurement, and therefore is a measure of the production rate of sGAG during that time period. Data is expressed as a ratio between treated and untreated controls. Administration of LMP-1 (via AdLMP-1 at MOI 25) provided the highest sGAG level, which was 3.1±0.2 times that of the control (p<0.01). There was no significant difference in sGAG levels in media between cells treated withMOI 25 orMOI 50. Because this AdLMP-1 dose ofMOI 25 was the lowest dose that could achieve the maximal sGAG response, the inventors choseMOI 25 as the working dose for the remainder of the experiments. - A time-course experiment was carried out to determine the effect of varying the length of the experiment after treatment with AdLMP-1 at
MOI 25. Annulus cells were treated with LMP-1 (AdLMP-1 at MOI 25), and the production of sGAG over three day increments were measured. The results were normalized by DNA content at each time point and expressed as a ratio to untreated controls from the same time point. The sGAG level was increased to 1.6±0.2 p<0.01) onday 3, to 2.9±0.1 (p<0.01) onday 6, and to 2.8±0.1 (p<0.01) on day 9. No increase in sGAG level was noted betweenday 6 and day 9, indicating that a pleateau level was achieved byday 6. - LMP-1 Induction of Aggrecan Synthesis
- Because aggrecan is the predominant proteoglycan of the intervertebral disc, aggrecan core protein mRNA levels were measured 6 days after treatment with AdLMP-1. Quantitative real-time PCR methods were used and the data are presented as a ratio to untreated controls. After AdLMP-1 treatment (MOI 25), aggrecan mRNA level was 2.1±0.1 (p<0.01) times that of controls. After AdLacZ treatment (MOI 25) aggrecan mRNA level was unchanged, 1.0±0.16 times that of controls. These results, together with the sGAG experiments, demonstrated that LMP-1 stimulates intervertebral disc cell production of proteoglycans.
- Having established the dose and timing necessary for optimal AdLMP-1 activity on our culture system, the inventors then compared the effect of LMP-1, as administered via AdLMP-1, on annulus and nucleus cells. Rat annulus and nucleus cells were treated with AdLMP-1 at
MOI 25 and the sGAG concentration of each cell type was measured onday 6. The sGAG concentration was normalized by DNA content in order to account for minor variations in cell number. The results were not normalized to untreated controls in order to compare the untreated controls of annulus and nucleus cell types. The results for untreated annulus and nucleus cells were 0.6±0.04 sGAG/DNA and 1.0±0.12 sGAG/DNA respectively. This difference was statistically significant (p<0.05) and indicated that untreated nucleus cells produce more sGAG per cell than annulus cells. After AdLMP-1 treatment the results for annulus and nucleus cells were 1.5±0.08 sGAG/DNA (p<0.01) and 2.4±0.1 sGAG/DNA (p<0.01) respectively. These values indicated statistically significant increases compared to their respective untreated controls. The relative increases from untreated to AdLMP-1 treated cells were similar between annulus and nucleus cells. The cell number atday 6 with and without AdLMP-1 treatment was determined by measuring the DNA content. The annulus cell DNA content increased 1.2 times compared to untreated controls (p<0.01), but nucleus cell DNA content was unaffected by AdLMP-1. This indicated that LMP-1 induced a mild but significant increase in the number of annulus cells but not nucleus cells. - In order to test the effect of administration of LMP-1 (via AdLMP-1) on sGAG production in vitro for a period of weeks, the inventors used an alginate culture system. Alginate provides a three-dimensional matrix for cells that is important for maintenance of chondrocytic phenotype in long term in vitro cultures. Annulus cells grown in monolayer were treated with AdLMP-1 at
MOI 25 then transferred to alginate culture 24 hours later. The cells were cultured for periods of 1, 2, and 3 weeks. At 1 week, the sGAG level in the AdLMP-1 group was 1.5±0.06 (p<0.01) times that of untreated control (FIG. 5 ). At 2 weeks, the sGAG in the AdLMP-1 treated group increased to 2.9+0.3 (p<0.01) times that of untreated controls. This difference was maintained at 3 weeks; the sGAG level in the AdLMP-1 treated group was 2.9±0.1 (p<0.01) times that of controls. This indicated that AdLMP-1 was effective in maintaining increased sGAG accumulation in alginate for at least 3 weeks in culture. - Having demonstrated the effect of LMP-1 over-expression on proteoglycan production, we investigated the mechanism by which LMP-1 over-expression induced this effect. The time-course of changes in mRNA of over-expressed LMP-1 and BMPs (BMP-2, 4, 6, and 7) were determined. These BMPs had previously been shown to be stimulated in leukocytes and osteoblasts by LMP-1 over-expression.
- The time-dependent changes in over-expressed LMP-1 after annulus cell treatment with AdLMP-1 at
MOI 25 were determined. The data were expressed as a percent of the maximal mRNA level of over-expressed LMP-1 (day 6) instead of as ratio to untreated controls because no over-expressed LMP-1 mRNA was detectable in controls. LMP-1 mRNA was detectable 12 hours after treatment and continued to increase up to the last time point checked (day 6). This indicated that over-expressed LMP-1 could have an effect on downstream genes as early as 12 hours after LMP-1 administration. - The time-course of BMP mRNA levels after treatment with AdLMP-1 at
MOI 25 were also determined by real-time PCR and calculated as a ratio to untreated controls at each time point. BMP-2 mRNA was upregulated early, reaching a statistically significant (p<0.01) increase at 12 hours after LMP-1 treatment. BMP-2 mRNA increase reached a plateau level byday 3. BMP-7 mRNA was upregulated later than BMP-2, reaching statistically significantly increase at day 3 (p<0.01) and day 6 (p<0.01). Neither BMP-4 nor BMP-6 mRNA levels were significantly different from those of untreated controls. - Having established that LMP-1 mRNA over-expression provides up-regulation of BMP-2 and BMP-7 mRNAs in annulus cells, the inventors tested whether this mRNA increase correlated with increased secretion of the BMP proteins into the culture media. An ELISA assay to quantitate the level of BMP-2, 4, 6, and 7 proteins in the conditioned media. Annulus cells cultured in monolayer were treated with AdLMP-1 at
MOI 25. Media was changed once atday 3, and media was analyzed atday 6. Test samples therefore contained BMPs secreted during the last 3 days (day 4 to 6) of culture. Protein levels of BMP-2 and BMP-7 in the media were 3.5±0.4 (p<0.01) and 2.5±0.3 (p<0.05) times that of untreated controls, respectively. BMP-4 and BMP-6 protein levels were not significantly different from those of untreated control, which is consistent with the results obtained for mRNA. - Since the mRNA and protein of BMP-2 and BMP-7 were upregulated by LMP-1, the inventors investigated whether blocking these BMPs would prevent the increase in sGAG production induced by LMP-1. Annulus cells cultured in monolayer with AdLMP-1 at
MOI 25 were simultaneously treated with the BMP inhibitor noggin in the culture media and the sGAG levels were measured atday 6. Cells treated with AdLMP-1 alone had increased sGAG levels (2.7±0.3 times that of untreated control), whereas cells treated with noggin at 3200 ng/ml and AdLMP-1 atMOI 25 had unchanged sGAG levels (1.1±0.1 times untreated control), indicating that noggin completely blocked the effect of AdLMP-1. Cells treated with noggin alone (3200 ng/ml) still had nearly unchanged sGAG level (0.8+0.1 times untreated control), indicating the absence of a toxic effect by noggin. The inhibitory effect of noggin on AdLMP-1 induced sGAG production was concentration dependent. - Endogenous levels of aggrecan, BMP-7, and LMP-1 mRNA in the control discs (AdGFP injected discs) were detected in the nucleus pulposus. Endogenous mRNA levels were used to calculate the increase in aggrecan, BMP-7, and LMP-1 mRNA in the AdLMP-1 injected discs. Discs injected with AdLMP-1 expressed 830% higher levels of total LMP-1 mRNA than the discs injected with AdGFP. Administration of LMP-1 via AdLMP-1 produced an 1100% increase in the BMP-7 mRNA level over control (p<0.05). Aggrecan mRNA level was increased by 66% over control (p<0.05).
- Endogenous levels of BMP-2, BMP-7, LMP-1, and aggrecan mRNA were also detected. A correlation between increasing AdLMP-1 dose and total LMP-1 mRNA was seen. Administration of LMP-1 via AdLMP-1 significantly increased BMP-2 and BMP-7 mRNA levels maximally at a dose of 107 pfu per disc (p<0.05) AdLMP-1 at a dose of 107 pfu per disc led to the highest increase in aggrecan mRNA, 50% over control (P<0.05).
- Administration LMP-1 to intervertebral disc cells resulted in an increase in sGAG production and an increase in aggrecan mRNA levels. LMP-1 administration produced an increase in the mRNA and protein levels of BMP-2 and BMP-7 in vitro, and the effect of LMP-1 administration on upregulation of proteoglycan production could be blocked by administration of the BMP inhibitor noggin.
- Sprague-Dawley rats aged 11 months were euthanized and intervertebral disc tissue from the lumbar spine and tail were harvested in under sterile conditions. Annulus fibrosus and nucleus pulposus were separately dissected and diced. The intervertebral disc tissue was placed in Dulbecco's modified Eagle's medium and Ham's F12 medium (DMEM/F-12; GIBCO BRL, Grand Island, N.Y., U.S.A.) containing 100 unit/ml penicillin and 100 mg/ml streptomycin. The intervertebral disc tissue was treated with 0.2% pronase (Sigma Chemical, St. Louis, Mo., U.S.A.) in the medium for 1 hour at 37° C. and then treated with 0.025% collagenase (Sigma Chemical, St. Louis, Mo., U.S.A.) for 6 hours at 37° C. Isolated cells were washed and filtered through a 70 mm mesh (Falcon, Franklin Lakes, N.J., U.S.A.) into 75 cm2 flasks with 12 ml DMEM/F-12 medium containing 10% fetal bovine serum (FBS), 100 unit/ml penicillin, 100 mg/ml streptomycin, 2 mM L-glutamine and 50 mg/ml ascorbate. The cells were grown at 37° C. in 5% CO2 with humidification. The culture media was changed every 2 days for approximately 8 days.
- Two different viruses were used. The replication
deficient type 5 Adenovirus containing the human LMP-1 cDNA driven by a CMV promoter (AdLMP-1) was used as the experimental virus. The control virus consisted of a similar replicationdeficient type 5 adenovirus containing the lacZ cDNA. - When the primary culture of intervertebral disc cells became confluent, the cells were subcultured into 6-well plates at 400,000 cells per well. Three days later, the cells were treated with adenovirus containing the cDNA for either the human LMP-1 gene (AdLMP-1) or the LacZ gene (AdLacZ). Cell number was determined at
day 0 by counting a control well using a hemocytometer. The viral dose was expressed as a multiplicity of infection (MOI), the number of plaque-forming unit (pfu) per cell. This is essentially the number of recombinant adenoviral plaque-forming units to which a single intervertebral disc cell was exposed. The cultured cells were treated for thirty minutes at 37° C. with AdLMP-1 or AdLacZ in 300 ml of DMEM/F-12 with 0% FBS at different MOIs (o, 10, 25, 50) as designated in each experiment. Then the culture volume was raised to 2.0 ml with DMEM/F-12 medium containing 1% FBS, 100 unit/ml penicillin, 100 mg/ml streptomycin, 2 mM L-glutamine and 50 mg/ml Vitamin C. The medium was changed every 3 days during the experiment. - The sulfated-glycosaminoglycan (sGAG) content of the culture media was assayed using the 1,9-dimethylmethylene blue (DMMB) method. The
culture media 2 ml was centrifuged (5000×G for 30 minutes) to concentrate the sGAG using the Centricon YM-50 centrifugal filter (Millipore Co., Bedford, Mass., U.S.A.). The sample solution (20 ml) were mixed gently with 200 ml DMMB dye solution in a 96-well microtiter plate, and the optical density (OD) was checked immediately at 520 nm wavelength filter. A standard curve was constructed using serial dilutions of chondroitin sulfate (Sigma Chemical, St. Louis, Mo., U.S.A.). Total sGAG in the media were normalized by DNA content and presented as a ratio to the untreated control. - The cell number was determined by the DNA content of each well, and DNA content was measured with a Hoechst dye 33258 (Polysciences, Warrington, Pa., U.S.A.) method, as previously described. Cultured cells were removed from the plate by exposure to papain (10 units/ml). Cells were then pelleted and incubated at. 60° C. for 3 hours. A twenty microliter aliquot of the papain digest was mixed with 200 ml of Hoechst dye 33258 solution in a 96-well fluoroplate. Emission and excitation spectra were measured in Luminescence Spectrometer LS 50B (Perkin-Elmer, Wellesly, Mass., U.S.A.) at 456 nm and 365 nm, respectively. Standard curves were generated at the time of each measurement using known concentrations of calf thymus DNA (Sigma Chemical, St. Louis, Mo., U.S.A.).
- Alginate bead cultures are useful for maintaining chondrocytic phenotype in long term cultures. This method was to determine the effect of AdLMP-1 in three week cultures. The cells were treated in monolayer cultures as described above. One day later, the cells were released by trypsinization and washed 2 times with media. The isolated cells were resuspended in 0.6% low-viscosity sterile alginate (Sigma Chemical, St. Louis, Mo., U.S.A.) solution at 600,000 cells/ml. The cells were dispensed into a 0.102M CaCl+0.15M NaCl solution in a dropwise fashion through a 21-gauge needle attached to 10-ml plastic syringe in order to form the alginate beads. After 10 minutes the newly formed beads (containing approximately 12,000 cells/bead) were washed three times with sterile 0.9% NaCl solution followed by two washes with DMEM/F-12. The beads containing the annulus fibrosus cells were separately cultured in 6 wells plate with DMEM/F-12 medium containing 1% FBS, 100 unit/ml penicillin, 100 mg/ml streptomycin, 2 mM L-glutamine and 50 mg/ml Vitamin C. The media was changed every two days for different time periods (1, 2, and 3 weeks). The alginate beads were dissolved in 350 ml sodium citrate buffer (55 mmol/L Na-citrate, 50 mmol/L EDTA, 150 mmol/L NaCl, pH7.4). Cells were pelleted with centrifugation and the sGAG content in the dissolved solution was measured with the DMMB method described above. The sGAG content that remained the cell pellet was negligible compared to that in the suspension. The results were described as fold increase over untreated control group using sGAG of dissolved solution.
- Quantification of mRNA Levels.
- Real-time PCR was used to determine mRNA levels of BMP-2, BMP-4, BMP-6, BMP-7, and over-expressed LMP-1 in a quantitative fashion. The primers for all of the genes were validated by determining the product size on an agarose gel and by DNA sequencing the amplicon. 18S levels were determined in each sample to use as an internal control.
- Total RNA of each sample was extracted by a single-step method using a guanidium thiocyanate-phenol-chloroform technique. The concentration of the isolated RNA was determined with a spectrophotometer (DU-500; Beckman, Fullerton, Calif., U.S.A.) at 260 nm wavelength. The RNA was treated with DNAse 1 (Ambion, Inc. Texas, U.S.A.) to remove DNA contamination of the samples. Reverse transcription was carried out in 40 ml volume with 2 mg of total RNA; 30U Avian Myeloblastosis virus reverse transcriptase (Promega, Madison, Wis., U.S.A.); 5 mM of MgCl2; 60 U/ml of RNAsin (Promega, Madison, Wis., U.S.A.); 1 mM of each deoxyadenosine triphosphate (dATP), deoxycytidine triphosphate (dCTP), deoxyguanidine triphosphate (dGTP), deoxythymidine triphosphate (dTTP); and 1 mg oligo(dT)15 primer for 45 minutes at 42° C. PCR was performed for 30 cycles (95° C., 30″; 62° C., 30″; 72° C., 45″) with Amplitaq® DNA polymerase. To confirm the absence of DNA contamination, RNA samples treated without reverse transcriptase were also subjected to PCR: the absence of PCR product confirmed the lack of DNA contamination.
- Real-time PCR has been reported to be a rapid, reliable, and reproducible method for quantitative detection of specific mRNAs. A real-time PCR method using SYBR® Green Real-Time PCR Kit (Applied Biosystems, Foster City, Calif., U.S.A.) was used to perform quantitative mRNA analysis of BMP-2, BMP-4, BMP-6, BMP-7, and aggrecan. Twenty-five microliters (25 ml) of reaction volume included 5 ml of cDNA, 3.75 picomole of each primer (BMP-2,-4,-6,-7 and 18S), and 12.5 ml of SYBR® Green master mix (2×, Biorad, Hercules, Calif., U.S.A.). To quantify mRNA levels of over-expression LMP-1 and 18S, real-time PCR method using TaqMan® Real-Time PCR Kit (Applied Biosystems, Foster City, Calif., U.S.A.) was also performed. Twenty-five microliters (25 ml) of reaction volume included 5 ml of cDNA, 3.75 pmol of each primer, and 12.5 ml of TaqMan® PCR master mix (2×, Biorad, Hercules, Calif., U.S.A.).
- Real-time PCR was performed with the following 3 step protocol; step 1: 50° C. for 2 minutes, step 2: 95° C. for 10 minutes, and step 3: (95° C. for 15 seconds, 60° C. for 1 minute)×45 cycles using the GeneAmp®; 5700 Sequence Detection system (Applied Biosystems, Foster City, Calif., U.S.A.). To confirm amplification specificity, the PCR products were subjected to a dislocation curve analysis. Threshold cycles (Ct) of each reaction were standardized according to 18S using the comparative-ΔΔCt method, as described previously.
- ELISA assay for
BMP - Standard curves of BMPs were constructed using increasing concentrations (0.1 ng/100 μL per well to 1000 ng/100 μL per well) of
human BMP BMP - To quantitate the results, linear regression plots were made for each standard. In all cases, the concentrations of samples were extrapolated from the linear regression plots of the standard in according to the corresponding values at the same absorbance as the standards.
- BMP Inhibition by Noggin Glycoprotein
- Noggin is a glycoprotein that binds to BMP-2, 4, 6, and 7 in a highly specific manner and prevents these BMPs from activating their cognate receptors. A form of mouse noggin (noggin-FC Sigma Chemical, St. Louis, Mo., U.S.A.) was used in experiments to determine the effect of specifically blocking BMPs after AdLMP-1 treatment. Noggin at different concentrations (100, 200, 400, 800, 1600 and 3200 ng/ml) was applied to cells on
day 0 andday 3 after AdLMP-1 (MOI 25) treatment. Onday 6, the conditioned media were assayed to examine sGAG production using the DMMB method described above. Results indicated that LMP-1 effects could be blocked by administration of Noggin, demonstrating that LMP-1 activity is, in part, related to its induction of BMPs.
Claims (43)
Priority Applications (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US10/806,915 US7892532B2 (en) | 1999-04-30 | 2004-03-23 | Intracellular delivery of osteoinductive proteins and peptides |
US11/602,120 US7781574B2 (en) | 2001-11-14 | 2006-11-20 | Chimeric osteogenic factor containing proteins capable of increased nuclear localization and methods of use thereof |
US11/633,963 US7691814B2 (en) | 2003-03-24 | 2006-12-05 | Osteogenic compositions comprising an amino acid sequence capable of being phosphorylated by CAMK2 |
US11/875,267 US8252738B2 (en) | 1999-04-30 | 2007-10-19 | Method for changing cell phenotype using LIM mineralization proteins |
US12/127,586 US20080292599A1 (en) | 1999-04-30 | 2008-05-27 | Chondrogenic Compositions and Methods of Use |
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US13202199P | 1999-04-30 | 1999-04-30 | |
US09/959,578 US7045614B1 (en) | 1999-04-30 | 2000-04-28 | LIM mineralization protein splice variants |
PCT/US2000/011664 WO2000066178A1 (en) | 1999-04-30 | 2000-04-28 | Lim mineralization protein splice variants |
US45655103P | 2003-03-24 | 2003-03-24 | |
US10/806,915 US7892532B2 (en) | 1999-04-30 | 2004-03-23 | Intracellular delivery of osteoinductive proteins and peptides |
Related Parent Applications (5)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US09/959,578 Continuation-In-Part US7045614B1 (en) | 1997-04-30 | 2000-04-28 | LIM mineralization protein splice variants |
PCT/US2000/011664 Continuation-In-Part WO2000066178A1 (en) | 1999-04-30 | 2000-04-28 | Lim mineralization protein splice variants |
US95957800A Continuation-In-Part | 1997-07-30 | 2000-04-28 | |
US10/806,915 Continuation-In-Part US7892532B2 (en) | 1999-04-30 | 2004-03-23 | Intracellular delivery of osteoinductive proteins and peptides |
US11/875,267 Continuation-In-Part US8252738B2 (en) | 1999-04-30 | 2007-10-19 | Method for changing cell phenotype using LIM mineralization proteins |
Related Child Applications (6)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10/292,951 Continuation-In-Part US7923250B2 (en) | 1997-07-30 | 2002-11-13 | Methods of expressing LIM mineralization protein in non-osseous cells |
US10/806,915 Continuation-In-Part US7892532B2 (en) | 1999-04-30 | 2004-03-23 | Intracellular delivery of osteoinductive proteins and peptides |
US11/385,612 Continuation-In-Part US7504374B2 (en) | 2000-10-24 | 2006-03-21 | Method for inducing deposition and maturation of bone comprising a co-therapeutic regimen of LMP-1 and BMP-2 |
US11/602,120 Continuation-In-Part US7781574B2 (en) | 2001-11-14 | 2006-11-20 | Chimeric osteogenic factor containing proteins capable of increased nuclear localization and methods of use thereof |
US11/633,963 Continuation-In-Part US7691814B2 (en) | 2003-03-24 | 2006-12-05 | Osteogenic compositions comprising an amino acid sequence capable of being phosphorylated by CAMK2 |
US11/875,267 Continuation-In-Part US8252738B2 (en) | 1999-04-30 | 2007-10-19 | Method for changing cell phenotype using LIM mineralization proteins |
Publications (3)
Publication Number | Publication Date |
---|---|
US20040197867A1 US20040197867A1 (en) | 2004-10-07 |
US20080166755A9 true US20080166755A9 (en) | 2008-07-10 |
US7892532B2 US7892532B2 (en) | 2011-02-22 |
Family
ID=33101253
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10/806,915 Expired - Fee Related US7892532B2 (en) | 1999-04-30 | 2004-03-23 | Intracellular delivery of osteoinductive proteins and peptides |
Country Status (1)
Country | Link |
---|---|
US (1) | US7892532B2 (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20090110637A1 (en) * | 2007-10-26 | 2009-04-30 | Warsaw Orthopedic, Inc. | LMP and Regulation of Tissue Growth |
Families Citing this family (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20080193500A1 (en) * | 2007-02-14 | 2008-08-14 | Mckay William F | Effect of LMP-1 overexpression on large and small proteoglycans of the disc |
US7781574B2 (en) * | 2001-11-14 | 2010-08-24 | Emory University | Chimeric osteogenic factor containing proteins capable of increased nuclear localization and methods of use thereof |
US7691814B2 (en) * | 2003-03-24 | 2010-04-06 | Emory University | Osteogenic compositions comprising an amino acid sequence capable of being phosphorylated by CAMK2 |
WO2005111058A1 (en) * | 2004-04-13 | 2005-11-24 | Medtronic Sofamor Danek, Inc | Intracellular delivery of osteoinductive proteins and peptides |
EP1863850B1 (en) * | 2005-03-30 | 2009-09-23 | Jung Moon Kim | Non-activated polypeptides having a function of tissue regeneration and method for preparing the same |
KR100775958B1 (en) | 2005-03-30 | 2007-11-13 | 김정문 | Non-activated Polypeptides Having a Function of Tissue Regeneration and Method for Preparing the Same |
GB0515115D0 (en) * | 2005-07-22 | 2005-08-31 | Isogenica Ltd | Peptide characterisation |
KR20090034239A (en) * | 2007-10-02 | 2009-04-07 | 재단법인서울대학교산학협력재단 | Cell permeable fusion protein for facilitating ossification and use thereof |
WO2009143141A1 (en) * | 2008-05-19 | 2009-11-26 | Case Western Reserve University | Method for treating cd40-mediated diseases |
WO2014011540A1 (en) | 2012-07-09 | 2014-01-16 | Emory University | Bone morphogenetic protein pathway activation, compositions for ossification, and methods related thereto |
US20160060312A1 (en) * | 2014-08-27 | 2016-03-03 | Cellivery Therapeutics, Inc. | Development of Protein-Based Biotherapeutics That Penetrates Cell-Membrane and Induces Anti-Pancreatic Cancer Effect - Improved Cell-Permeable Suppressor of Cytokine Signaling (iCP-SOCS3) Proteins, Polynucleotides Encoding the Same, and Anti-Pancreatic Cancer Compositions Comprising the Same |
JP2018500135A (en) | 2014-12-29 | 2018-01-11 | バイオヴェンタス・エルエルシー | Improved delivery system and method of osteoinductive molecules in bone repair |
CN113713170B (en) * | 2021-08-26 | 2022-07-29 | 深圳市人民医院 | MBMP2 protein composite hydrogel and preparation method and application thereof |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5580775A (en) * | 1992-05-01 | 1996-12-03 | Emory University | High affinity, brain-specific nucleic acids encoding a L-proline transporter, and vectors, and host cells comprising the same |
US5652122A (en) * | 1989-12-21 | 1997-07-29 | Frankel; Alan | Nucleic acids encoding and methods of making tat-derived transport polypeptides |
US6300127B1 (en) * | 1997-07-30 | 2001-10-09 | Emory University | Bone mineralization proteins, DNA, vectors, expression systems |
US6475516B2 (en) * | 1996-04-12 | 2002-11-05 | Dicosmo Frank | Drug delivery via therapeutic hydrogels |
US20030180266A1 (en) * | 1997-07-30 | 2003-09-25 | Mckay William F. | Methods of expressing LIM mineralization protein in non-osseous cells |
US20030225021A1 (en) * | 2001-11-14 | 2003-12-04 | Mckay William F. | Methods of inducing the expression of bone morphogenetic proteins (BMPs) and transforming growth factor-beta proteins (TGF-betas) in cells |
-
2004
- 2004-03-23 US US10/806,915 patent/US7892532B2/en not_active Expired - Fee Related
Patent Citations (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5652122A (en) * | 1989-12-21 | 1997-07-29 | Frankel; Alan | Nucleic acids encoding and methods of making tat-derived transport polypeptides |
US5580775A (en) * | 1992-05-01 | 1996-12-03 | Emory University | High affinity, brain-specific nucleic acids encoding a L-proline transporter, and vectors, and host cells comprising the same |
US6475516B2 (en) * | 1996-04-12 | 2002-11-05 | Dicosmo Frank | Drug delivery via therapeutic hydrogels |
US6300127B1 (en) * | 1997-07-30 | 2001-10-09 | Emory University | Bone mineralization proteins, DNA, vectors, expression systems |
US6444803B1 (en) * | 1997-07-30 | 2002-09-03 | Emory University | Bone mineralization proteins, DNA, vectors, expression systems |
US6521750B2 (en) * | 1997-07-30 | 2003-02-18 | Univ Emory | Bone mineralization proteins, DNA, vectors, expression systems |
US20030180266A1 (en) * | 1997-07-30 | 2003-09-25 | Mckay William F. | Methods of expressing LIM mineralization protein in non-osseous cells |
US6858431B2 (en) * | 1997-07-30 | 2005-02-22 | Medtronic Sofamor Danek | Bone mineralization proteins, DNA, vectors expression systems |
US20030225021A1 (en) * | 2001-11-14 | 2003-12-04 | Mckay William F. | Methods of inducing the expression of bone morphogenetic proteins (BMPs) and transforming growth factor-beta proteins (TGF-betas) in cells |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20090110637A1 (en) * | 2007-10-26 | 2009-04-30 | Warsaw Orthopedic, Inc. | LMP and Regulation of Tissue Growth |
Also Published As
Publication number | Publication date |
---|---|
US7892532B2 (en) | 2011-02-22 |
US20040197867A1 (en) | 2004-10-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US7892532B2 (en) | Intracellular delivery of osteoinductive proteins and peptides | |
US7041645B2 (en) | Methods of inhibiting or inducing bone formation | |
CA2708549A1 (en) | Bmp mutants with decreased susceptibility to noggin | |
JP2008086319A (en) | Polypeptide variant with raised heparin-binding capacity | |
US20150057223A1 (en) | High activity growth factor mutants | |
US20180009865A1 (en) | Bmp-2 peptides and methods of use | |
US9951112B2 (en) | BMP-4 peptides and methods of use | |
AU2004317501B2 (en) | Intracellular delivery of osteoinductive proteins and peptides | |
US20100279940A1 (en) | Chimeric osteogenic factor containing proteins capable of increased nuclear localization and methods of use thereof | |
US20180170988A1 (en) | Bmp-7 peptides and methods of use | |
JP2008538073A (en) | Growth factor mutants with improved biological activity | |
EP2751258B1 (en) | Bmp peptides & methods of use | |
KR20100111899A (en) | Novel kgf2-fn10 fusion protein and its use for promoting skin regeneration | |
CA2517496A1 (en) | Intracellular delivery of osteoinductive proteins and peptides | |
KR101785502B1 (en) | A fusion protein of fibronectin protein and Bone morphogenetic protein-2 | |
KR20070072938A (en) | Intracellular delivery of osteoinductive proteins and peptides | |
US11078248B2 (en) | BMP peptides and methods of use | |
US20090214495A1 (en) | Vascular endothelial growth factor-d (vegf)-d and functionally fragments thereof for bone repairing |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: MEDTRONIC SOFAMOR DANEK, TENNESSEE Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:MARX, JEFFREY C.;REEL/FRAME:015461/0254 Effective date: 20040324 |
|
AS | Assignment |
Owner name: SDGI HOLDINGS, INC., DELAWARE Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:MEDTRONIC SOFAMOR DANEK;REEL/FRAME:016978/0226 Effective date: 20051026 Owner name: SDGI HOLDINGS, INC., DELAWARE Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:DRAPEAU, SUSAN;REEL/FRAME:016978/0204 Effective date: 20051027 |
|
AS | Assignment |
Owner name: EMORY UNIVERSITY, GEORGIA Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:TITUS, FRANCES LOUISA;BODEN, SCOTT D.;YOON, SANGWOOK T.;SIGNING DATES FROM 20051101 TO 20051129;REEL/FRAME:017113/0650 Owner name: EMORY UNIVERSITY, GEORGIA Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:TITUS, FRANCES LOUISA;BODEN, SCOTT D.;YOON, SANGWOOK T.;REEL/FRAME:017113/0650;SIGNING DATES FROM 20051101 TO 20051129 |
|
AS | Assignment |
Owner name: SDGI HOLDINGS, INC., DELAWARE Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:MEDTRONIC SOFAMOR DANEK;REEL/FRAME:017608/0218 Effective date: 20051026 Owner name: SDGI HOLDINGS, INC., DELAWARE Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:DRAPEAU, SUSAN;REEL/FRAME:017608/0168 Effective date: 20051027 |
|
AS | Assignment |
Owner name: WARSAW ORTHOPEDIC, INC., INDIANA Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:SDGI HOLDINGS, INC.;REEL/FRAME:019806/0305 Effective date: 20060428 |
|
STCF | Information on status: patent grant |
Free format text: PATENTED CASE |
|
CC | Certificate of correction | ||
FPAY | Fee payment |
Year of fee payment: 4 |
|
MAFP | Maintenance fee payment |
Free format text: PAYMENT OF MAINTENANCE FEE, 8TH YEAR, LARGE ENTITY (ORIGINAL EVENT CODE: M1552) Year of fee payment: 8 |
|
FEPP | Fee payment procedure |
Free format text: MAINTENANCE FEE REMINDER MAILED (ORIGINAL EVENT CODE: REM.); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY |
|
LAPS | Lapse for failure to pay maintenance fees |
Free format text: PATENT EXPIRED FOR FAILURE TO PAY MAINTENANCE FEES (ORIGINAL EVENT CODE: EXP.); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY |
|
STCH | Information on status: patent discontinuation |
Free format text: PATENT EXPIRED DUE TO NONPAYMENT OF MAINTENANCE FEES UNDER 37 CFR 1.362 |
|
FP | Lapsed due to failure to pay maintenance fee |
Effective date: 20230222 |